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Summary 
Syphilis is a chronic inflammatory disease transmitted by the spirochete 
Treponema pallidum. The bacterium is usually acquired by direct contact, 
generally sexual; the disease is worldwide spread and it represents an 
important global health problem. Syphilis is indeed a major sexually 
transmitted disease, particularly in developing countries, but an increasing 
number of new cases have also been recently noted in USA and Europe. 
Syphilis is a progressive and multistage disease with diverse and wide-
ranging manifestations.   
Syphilis is an evolving disease and can be divided in three main stages. In 
the first stage, a red papule appears at the site of inoculation, usually 
genitals. Within the first few days, the papule ulcerates, producing the 
typical chancre of primary syphilis, which is painless and filled with 
treponemes. The chancre is accompanied by regional lymphadenopathy. 
If untreated, bacteria can also proliferate in the chancre and can be 
transported via lymphatics to the bloodstream, from which they 
disseminate throughout the body, giving rise to secondary syphilis: this 
represents the second stage and is a systemic disease. The most 
common manifestation of secondary syphilis is a disseminated 
mucocutaneous rash, which usually resolves spontaneously. In untreated 
patients, the symptoms are absent for a variable period of time, which is 
called latent stage. Afterwards, one-third of untreated patients can develop 
symptomatic late syphilis: the third stage of the disease, which is 
subdivided into gummatous syphilis, neurosyphilis and cardiovascular 
syphilis.  
This disease could be cured with an antibiotic treatment, but, if not 
adequately treated, syphilis can lead patients to death. 
Nowadays there are no available vaccines to prevent syphilis in particular 
due to the difficulties in cultivating T. pallidum in vitro make more difficult 
to study this pathogen as well as the identification of its virulence factors. 
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Little is known about the mechanism by which the bacterium causes the 
clinical manifestations that accompany the different stages of the disease, 
however it is established that T. pallidum is able to invade and survive in a 
wide variety of tissues and organs and that it promotes the formation of 
new blood vessels. Angiogenesis could have a crucial role in syphilis 
pathogenesis, at least for two reasons: i) the bacterium has limited 
metabolic capabilitie, thus probably it requires support from the host and it 
may derive most essential macromolecules from the blood. ii) Increased 
vascular permeability is one of the first stages in angiogenesis and the 
organism could take advantage of the vascular leakage to access to and 
egress from the bloodstream, resulting in systemic spread.  
Another distinctive feature of syphilis consists in the fact that it becomes 
chronic in untreated patients and this probably reflects the ability of the 
bacterium in eliciting a T regulatory response, which could be associated 
with the fading of the host effector immune responses against the 
pathogen. We have recently demonstrated that the bacterioferritin TpF1, a 
major antigen of T. pallidum, plays a pivotal role in driving this suppressive 
immune response, by modulating the release of specific cytokines by 
monocytes.  
TpF1 is a protein homolog to another immunomodulant antigen produced 
by the bacterium Helicobacter pylori and called HP-NAP. Both these 
proteins belong to the Dps-like family, a versatile group of bacterial stress 
miniferritins with a nearly spherical dodecameric structure.  
HP-NAP, besides interacting with neutrophils, monocytes and dendritic 
cells and modulating their activity (as TpF1 does), also binds to endothelial 
cells, in which it is internalized by transcytosis. 
Considering the homology between HP-NAP and TpF1 and the fact that 
angiogenesis is a characteristic of the secondary syphilis, we wondered 
whether TpF1 could interact with endothelial cells and promote their 
proliferation.  
We have demonstrated that TpF1 induces proliferation and migration of 
human endothelial cells (HUVECs); moreover, the protein activates 
endothelial cells to form microcapillary-like structures in vitro inducing 
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marked changes in the cell pattern with the formation of tubules 
assembled by elongation and joining of the cells; a similar pattern was 
observed with VEGF.  With the aim of understanding the mechanism 
underlying the activity of TpF1, we have addressed the possibility of an 
indirect effect mediated by VEGF or IL-8, both proangiogenic factors. We 
have excluded any contribution by VEGF: indeed, the latter is not released 
by the endothelial cells upon TpF1 stimulation. On the contrary, we have 
found that TpF1 triggers the release of IL-8 and, notably, the blockage of 
the cytokine strongly prevents the angiogenic activity of the bacterial 
protein inhibiting endothelial cell proliferation, migration and micro 
capillary-like structures formation. We also verified that the secretion of IL-
8 relies on the induction of intracellular cAMP, produced by cellular 
adenylate cyclases, which is able to induce gene transcription through the 
activation of the two transcription factors NF-κB and CREB (cAMP 
response element-binding protein). 
Finally we have observed that TpF1 induces new blood vessels formation 
in vivo in a zebrafish model. Moreover TpF1 promotes, in zebrafish, IL-8 
gene expression suggesting a role for this cytokine in the TpF1-induced 
angiogenesis process also in vivo. 
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Sommario 
 
La sifilide è una malattia infiammatoria cronica trasmessa dalla spirocheta 
Treponema pallidum. Il batterio è spesso trasmesso attraverso contatto 
diretto, generalmente sessuale; la malattia è diffusa a livello mondiale e 
rappresenta ancora oggi un importante problema sanitario globale. La 
sifilide è, infatti, la principale malattia a trasmissione sessuale, 
specialmente nei paesi in via di sviluppo, un crescente numero di nuovi 
casi è comunque stato riscontrato anche in USA e in Europa. La sifilide è 
una malattia progressiva e multistadio con manifestazioni cliniche diverse 
e ad ampio raggio.  
La sifilide è una malattia in continua evoluzione ed è caratterizzata da tre 
stadi principali. Nel primo stadio, una papula rossastra appare nel sito d’ 
infezione, generalmente i genitali. Entro i primi giorni, la papula tende ad 
ulcerare, dando origine alla chancre tipica della sifilide primaria, una 
lesione indolore contenente un alto numero di treponemi. La chancre è 
inoltre accompagnata da linfoadenopatia regionale. Se la malattia non è 
trattata, i batteri possono proliferare all’interno della chancre e, attraverso 
la via linfatica, raggiungere il flusso sanguigno dal quale disseminano in 
tutto l’organismo dando così origine alla sifilide secondaria: questa 
rappresenta il secondo stadio della malattia ed ha carattere sistemico. Nei 
pazienti non trattati, i sintomi possono rimanere assenti per un periodo 
variabile di tempo denominato sifilide latente. Successivamente, un terzo 
dei pazienti non sottoposti a trattamento può sviluppare i sintomi 
dell’ultimo stadio della sifilide; la sifilide terziaria. La sifilide terziaria può 
essere a sua volta suddivisa in gomma sifilitica, neurosifilide e sifilide 
cardiovascolare. 
Questa malattia può essere curata attraverso una semplice terapia 
antibiotica ma, se non adeguatamente trattata, può portare alla morte del 
paziente. Ad oggi non sono ancora disponibili vaccini volti a prevenire la 
sifilide, in particolare la difficoltà di coltivare T. palliudm in vitro rende 
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complicato lo studio di questo patogeno e, quindi, l’identificazione dei suoi 
fattori di virulenza. 
Il meccanismo attraverso cui il batterio provoca le tipiche manifestazioni 
cliniche che accompagnano i differenti stadi della malattia risulta, ancora, 
perlopiù sconosciuto, ad ogni modo è stato dimostrato che T. pallidum è in 
grado di invadere e sopravvivere in un’ampia varietà di tessuti e organi  e 
che promuove la formazione di nuovi vasi sanguigni. L’angiogenesi 
potrebbe avere un ruolo cruciale nella patogenesi della sifilide almeno per 
due ragioni: i) il batterio ha limitate capacità metaboliche, dunque è 
probabile che esso richieda supporto dall’ospite e che derivi la maggior 
parte delle macromolecole essenziali dal sangue. ii) l’aumento della 
permeabilità vascolare è una delle prime fasi dell’angiogenesi e 
l’organismo potrebbe trarne vantaggio per accedere e uscire dal circolo 
sanguigno, portando ad una diffusione sistemica della malattia.  
Un’ulteriore caratteristica distintiva della sifilide risiede nella capacità di 
diventare cronica nei pazienti non trattati, una condizione che 
probabilmente riflette l’abilità del batterio nell’indurre una risposta T 
regolatoria la quale, a sua volta, può indurre l’indebolimento degli effettori 
della risposta immunitaria dell’ospite contro il patogeno. A tal proposito 
abbiamo recentemente dimostrato che la batterioferritina TpF1, uno dei 
principali antigeni di T. pallidum, gioca un ruolo fondamentale nel dirigere 
questa risposta immunitaria soppressiva, modulando il rilascio di 
specifiche citochine da parte dei monociti. 
TpF1 è una proteina omologa ad un altro antigene immunomodulante 
prodotto dal batterio Helicobacter pylori e chiamata HP-NAP. Entrambe 
queste proteine appartengono alla famiglia Dps-like, un gruppo variegato 
di mininferritine batteriche caratterizzate da una struttura dodecamerica 
approssimativamente sferica. 
HP-NAP, oltre ad interagire con neutrofili, monociti, cellule dendritiche e a 
modulare la loro attività (analogamente a TpF1), sono in grado di legare le 
cellule endoteliali nelle quali sono poi internalizzate per transcitosi. 
Considerando dunque l’omologia esistente tra HP-NAP e TpF1, e 
considerando che l’angiogenesi è una caratteristica peculiare della sifilide 
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secondaria, ci siamo chiesti se TpF1 potesse interagire con le cellule 
endoteliali e promuovere la loro proliferazione. 
Abbiamo dimostrato in primo luogo come TpF1 induca la proliferazione e 
la migrazione di cellule endoteliali umane (HUVEC); inoltre, la proteina è 
in grado di attivare le cellule endoteliali promuovendo la formazione di 
strutture simil-capillari in vitro attraverso l’induzione di marcate modifiche 
nella distribuzione cellulare e nella formazione di tubuli assemblati 
mediante l’elongazione e la giunzione delle cellule; un simile 
comportamento è stato osservato anche in presenze del VEGF.  
Al fine di comprendere il meccanismo alla base dell’attività di TpF1, 
abbiamo considerato la possibilità di un effetto indiretto mediato dal VEGF 
o da IL-8, entrambi fattori pro-angiogenici. Abbiamo escluso qualsiasi 
contributo del VEGF; quest’ultimo non viene rilasciato dalle cellule 
endoteliali in seguito al trattamento con TpF1. Al contrario, abbiamo 
osservato che la stimolazione con TpF1 promuove il rilascio di IL-8, in 
particolare, l’inibizione di tale citochina previene fortemente l’azione 
angiogenica indotta dalla proteina batterica inibendo la proliferazione 
cellulare, la migrazione e la formazione di strutture tubulari. Abbiamo 
inoltre osservato che la secrezione di IL-8 risiede nella produzione di 
cAMP, prodotto dall’adenilato ciclasi, il quale è in grado di indurre 
l’espressione genica attraverso l’attivazione dei due fattori di trascrizione 
NF-κB e CREB (cAMP response element-binding protein). 
Infine abbiamo verificato che TpF1 induce la formazione di nuovi vasi 
sanguigni in vivo, in un modello di zebrafish. Inoltre, TpF1 promuove 
anche in zebrafish l’espressione genica di IL-8 suggerendo dunque, anche 
in vivo, un ruolo per questa chemochina nel processo angiogenico indotto 
da TpF1. 
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Introduction 
1.1 Syphilis and Treponema pallidum 
1.1.1 Syphilis: an historical overview 
Syphilis is a chronic, inflammatory and usually sexually-transmitted 
disease, caused by the spirochaete Treponema pallidum subs. pallidum.  
Since it’s recognition as a new disease, in Europe in the 15th century, 
syphilis has been subject of great mystery and legend [1] (Figure 1). The 
name syphilis comes from a Latin poem, “Syphilis sive de morbo gallico”, 
describing an Italian shepherd boy, who contracted the “French disease” 
in the early 16th century [2]. 
 
                 
Figure 1. Angelo Bronzino. An Allegory, 1545 (formerly called, Venus, Folly,  
Cupid and Time) Courtesy  Trustees of  the National Gallery,  London [3]. 
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The first recorded epidemic of syphilis occurred in 1945 in Italy, when the 
French king Charles the VIII invaded Naples. When the invading army, 
including chiefly mercenaries, was disbanded and the soldiers returned 
home, syphilis was disseminate across Europe [4]. A number of prominent 
historical figures are reported, or assumed, to have contracted syphilis in 
the course of their lives. Francesco I de’ Medici (1541–1587), second 
Grand Duke of Tuscany, had suffered from malaria and syphilis [5]. 
 It is generally accepted that also Gerard de Lairesse (1641–1711), a 
draughtsman, theatrical set designer, lecturer, writer, theoretician, and one 
of the most celebrated Dutch renaissance painter suffered from congenital 
syphilis [6]. Sir William Osler’s, a canadian physician, uses Rembrandt’s 
Portrait (Figure 2) of de Lairesse to describe the stigmata of late 
congenital syphilis: 
 
 
 
 
 
 
 
 
 
 
 
 
          Figure 2. Rembrandt’s Portrait of de Lairesse  
      (The Metropolitan Museum of Art,  
      Robert Lehman Collection, 1975) [6] 
 
Although syphilis has been widely studied, the exact origin of the disease 
is still controversial. In this regard two main theories have been proposed: 
the Columbian theory (or New World theory) and the pre-Columbian 
theory (or Old World theory). The New World theory asserts that syphilis 
was endemic to the Caribbean and brought to Europe by Columbus’s crew 
after his first travel in 1942. On the contrary, the Old World theory 
“Growth is slow, development 
tardy, and there are facial and 
cranial characteristics which often 
render the disease recognizable 
at a glance. A young man of 
nineteen or twenty may neither 
look older or be more developed 
than a boy of ten or twelve [..] The 
forehead is prominent, the frontal 
eminences are marked, and the 
skull may be asymmetrical. The 
bridge of the nose is depressed, 
the tip retrousse´.The lips are 
often prominent, and there are 
striated lines running from the 
corners of the mouth.” 
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hypothesizes that the disease was endemic in central Africa and arrived in 
Europe long before Columbus’s voyage [7]. Recently, it has been 
developed a new hypothesis, which probably integrates the other two: the 
so-called Unitarian theory. This theory assess that treponematosis had a 
worldwide distribution and each social group was exposed to a kind of 
treponematosis characteristic to its geographic location, climatic condition 
and stage of cultural development. In other words, this theory supports the 
idea that different treponematosis such as yaws, bejel, pinta as well as 
syphilis, represent an adaptive responses of Treponema pallidum to 
peculiarities of the environment, culture, and contacts with other 
population [8].  
 
 
1.1.2 Syphilis: epidemiology 
Syphilis, which is only a human disease, since there is no animal 
reservoir, is usually transmitted by sexual contact or from mother to infant. 
T. pallidum may also occasionally be transmitted as a blood-borne 
infection. If left untreated, syphilis typically follows a prolonged course 
consisting of several stages. In a small proportion of cases, the infection 
can lead patients to death as consequence of neurological or 
cardiovascular complication. 
The disease represents an important global health problem counting the 
onset of approximately 12 million of new cases per year, with particular 
incidence in developing countries (Figure 3), due to lack of prenatal tests, 
antibiotics therapies or preventive measures; however, an increasing 
number of new cases have also been recently noted in the United States 
and Europe.  
Most cases occurs in sub-Saharan Africa, southeast Asia and south 
America, where congenital syphilis represents the main cause of perinatal 
and neonatal death [2]. Since the 1950s, periodic epidemics have been 
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observed in the United States, with peaks around 1990 followed by a 
progressive decline of prevalence from 1993 until 2000. 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 3. The global distribution of syphilis cases. [2] 
 
 
During the last decade, however, a significant increase in syphilis 
incidence has been reported in several countries, including the United 
States, Canada, and some areas of Central and Eastern Europe.  The 
main causes of the increased prevalence in syphilis epidemiology 
probably relies on sexual promiscuity, prostitution and a decreasing use of 
barrier protection due to a false sense of security that sexually transmitted 
diseases are currently curable and to a lack of pertinent knowledge. 
Nowadays, about 50–60% of new cases of syphilis occur in men who have 
sex with other men and are strongly associated with HIV and high-risk 
sexual behavior. Indeed, several studies report that patients who have 
been infected with HIV are susceptible to a co-infection with syphilis and 
vice versa, with 30-60% cases of co-infection with HIV in some urban 
centers such as Los Angeles, Chicago and Huston [7]. 
Over the past two centuries, syphilis symptoms have become less severe, 
thanks to the availability of effective treatments and to a concomitant 
decrease of the bacterium virulence if compared with epidemics of the XV 
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century. Syphilis pathogenesis has indeed changed over the time turning 
from an acute, debilitating and high morbidity disease, able to kill within a 
few years, into a chronic and milder form with infected patient who can 
survive for decades [9]. This evolution of the diseases towards a less 
aggressive form could result either from a progressive loss of virulence 
factors by the bacteria or from the fact that syphilis killed off the most 
susceptible population right at the beginning of its devastating existence 
[8]. 
 
 
 
1.1.3 Syphilis: pathogenesis and clinical manifestation 
Syphilis is a progressive and multistage disease with diverse and wide-
ranging manifestation, each characterized by a peculiar symptomatology. 
Once acquired, syphilis passes throughout a series of four different, but 
overlapping stages, commonly referred to as primary syphilis, secondary 
syphilis, latent syphilis and tertiary syphilis [7]. The stages of the disease 
were described for the first time by Philippe Record in the mid-1800s [1]. 
 
 
1.1.3.1 Primary syphilis 
The infection initiate when Treponema pallidum penetrates dermal micro 
abrasions or passes across intact mucosa, probably moving through the 
junctions between cells. The primary cutaneous lesion begins as a small 
red macule appearing at the site of inoculation, usually genitals. Within the 
first few days, the macule enlarges to a papule, with a range in diameter 
from 0.5 to 1.0 cm, and then ulcerates producing the typical chancre of 
primary syphilis (Figure 4). This sore is painless and filled with bacteria, is 
solitary round or oval; it has sharp indurated margins and a firm button-like 
cartilaginous base with a convex eroded surface and a raw-ham color; it 
shows a thin serous discharge and a hemorrhagic border without pus. The 
chancre is also accompanied by regional lymphadenopathy [10]. 
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Since the chancre is painless and usually located in an inconspicuous 
anatomical site, diagnosis of syphilis is sometimes delayed until later 
disease manifestation become apparent. Clinical evaluation can also be 
complicated by the fact that the appearance of primary chancres in some 
individuals does not fit the classic description; indeed, only about half of 
affected individuals has the typical chancre, while the other half shows a 
non-indurated ulcer with irregular border or chancroid-like lesion. 
 
 
 
 
 
 
 
 
Figure 4. Primary chancre [11] 
 
 
Usually, primary lesion develops 3 weeks after the infection and it resolves 
spontaneously within 4 to 6 weeks, but may still be discernible in about 
15% of patient at the onset of secondary syphilis. 
  
 
1.1.3.2 Secondary syphilis 
Although secondary syphilis generally appears after the healing of the 
chancre of primary syphilis, there is no a sharp demarcation between 
primary and secondary cutaneous syphilis [10]. 
Within hours from the infection, and during the evolution of primary stage, 
T. pallidum proliferates in the chancre and can be transported via 
lymphatic to the bloodstream, from which bacteria disseminate throughout 
the body, giving rise to the secondary syphilis: this represents the second 
stage of the disease that becomes systemic. The most common 
manifestation of secondary syphilis is a disseminated muco-cutaneous 
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rash (Figure 5). Pale and discrete macular lesions appear initially on the 
trunk and proximal extremities, on the palms of the hands and soles of the 
feet and, in 4% to 11% of patients, T. pallidum infection of hair follicles 
results in alopecia of the scalp.  
In rare individuals, lesion may become necrotic, a condition called lues 
maligna but, generally, the lesions are inconspicuous and may remain 
undetected [1]. 
 
 
    Figure 5. Mucocutaneous rash in  
     secondary syphilis [10] 
 
 
Although many patients with secondary syphilis do not experience any 
clinical evidence, the remaining patients display a variety of lesions 
including: sore throat, malaise, headache, fever, weight loss, nausea, 
arthritis, periostitis, myalgia [10]. Secondary syphilis can also be 
accompanied by gastric and renal involvement and hepatitis. 
Approximately 5% of individuals with secondary syphilis experiences early 
manifestation of neurosyphilis, including meningitidis and ocular disease 
[1]. 
 
1.1.3.3 Latent Syphilis 
If untreated in the primary or secondary stage, syphilis progresses to the 
latent stage during which the bacterium is probably localized in 
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immunologically privileged sites, that is usually characterized by absence 
of symptoms. The latent stage includes early latency and late latency. 
Patients with syphilis in the early latency stage remain infectious, whereas 
those with syphilis in the late latency stage are thought to be non-
infectious [12]. During latent syphilis, organisms may reach the 
bloodstream intermittently and can infect the developing fetus during 
pregnancy. Latent syphilis, if not cured by an antibiotic therapy evolves 
into the tertiary syphilis [1].  
 
 
1.1.3.4 Tertiary syphilis 
About one-third of individuals with latent syphilis develops the typical 
clinical manifestation of tertiary syphilis [1].  
Tertiary syphilis is mainly characterized by a persistent low-level burden of 
pathogens, against which a potent and detrimental immune response is 
mounted [12]. In this regard, it is believed that many of the protean 
symptoms of secondary and tertiary human syphilis, are manifestation of 
immune reactions that fail to clear the organism. The inability of the host in 
eliminating the microorganism results in a chronic inflammatory response 
that, in turn, can culminate in the tissue destruction [10] (see below).  
Tertiary syphilis is characterized my three main clinical manifestations: the 
gumma (15% of untreated patients), cardiovascular syphilis (10% of 
untreated patients) and late neurosyphilis (6.5% of untreated patients) [1]. 
 
 
• The gumma: it is a granulomatous, nodular lesion with variable 
central necrosis (Figure 6) (Lanfond & Lukehart, 2006). The 
formation of a granuloma reflects the inability of the host in 
removing the cause of an inflammation (foreign body or infectious 
agent), despite a strong recruitment and activation of macrophages 
at the site affected. Macrophages are often arranged around a 
central necrotic zone, essentially walling off the necrotic tissue, and 
exhibit an epithelioid appearance. Surrounding the epithelioid cells 
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are varying numbers of lymphocytes, plasma cells, macrophages, 
along with fibroblasts and connective tissue scaring [10]. 
 
         
  Figure 6. Tertiary cutaneous syphilis - the gumma [10] 
 
 
These destructive lesions most commonly affect the skin and 
bones, but they may also occur in the liver, heart, brain, stomach 
and upper respiratory tract.  
The gumma is the most characteristic lesion of tertiary syphilis but, 
unless it affects a vital organ, does not cause serious complication: 
for this reason it is also defined as “late benign syphilis” [1]. 
 
• Cardiovascular syphilis: prior to the advent of penicillin therapy, 
most of the deaths caused by syphilis were associated with 
cardiovascular impairment. Typically, one of the most frequent 
alterations of the cardiovascular system during syphilis, is 
represented by aortitis, an inflammation mainly concerning the 
ascending aorta. In most of cases aortitis is uncomplicated and 
asymptomatic.  
If a complication occurs, in 10% of individuals with untreated 
syphilis, it may be aortic regurgitation, coronary ostial stenosis or 
saccular aneurysm [1]. 
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• Neurosyphilis: in untreated or undertreated patients, T. pallidum 
can reach the cerebrospinal fluid. In this scenario four possible 
events may occur: spontaneous resolution, asymptomatic 
neurosyphilis, syphilitic meningitidis, or progression to late 
neurosyphilis [7].  
The most common symptoms of neurosyphilis include vertigo, 
insomnia, personality changes, loss of consciousness and epilepsy 
[1]. 
 
1.1.3.5 Congenital Syphilis 
Despite the fact that T. pallidum, in most cases, is sexually acquired, it can 
be also transmitted from mother to foetus at any time during pregnancy, 
resulting, if untreated, in congenital syphilis.  
Antibiotic treatment of the mother during the first six months of pregnancy 
is, in many cases, sufficient to prevent negative outcomes, but later 
treatment or lack of treatment may result in foetal death, foetal damage, or 
birth of an infected infant. Like the acquired syphilis, congenital syphilis 
includes different stages: early congenital syphilis (manifestations appears 
within 2 years of life; usually after 2 or 10 weeks after the delivery), late 
congenital syphilis (manifestation appears after 2 years of life), and 
residual stigmata.  The first symptom of early syphilis (up to 50% of new-
borns) is a persistent rhinitis, named “snuffles”, caused by T. pallidum 
invasion of the nasal mucosa. The bacterium can further invade the bones 
and cartilage of the nose and palate, leading to gummatous destruction 
later in life. Early congenital syphilis is also characterized by skin lesions 
resembling those of the secondary disease of adults, usually accompanied 
by desquamation of the skin of palms and soles, condylomata lata, and 
mucous patches.  Manifestations of late congenital syphilis usually appear 
two years after birth; between 5 to 25 years after birth, interstitial keratitis 
may cause damage to the cornea and iris, and eighth-nerve deafness may 
be apparent. Other signs include neurosyphilis, arthropathy, bilateral 
effusion of the knees and elbows, gummatous periostitis of the palmate 
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and nasal septum. Many of these manifestations progress despite an 
adequate treatment [1].  
 
 
1.1.4 Diagnosis and treatment 
For most of the 20th century, the gold standard method for the diagnosis of 
syphilis was the direct identification of T. pallidum by dark field microscopy 
or by direct fluorescent antibody test (DFA). Both methods were applied 
on the exudate of the lesions or on the infected tissue and they 
represented the main diagnostic methods for primary syphilis. The 
accuracy of dark field microscopy strongly relies on the operator’s 
experience and does not permit to discriminate between T. pallidum and 
non-pathogenic commensal treponemal species [4]. 
A Tp-specific polymerase chain reaction (Tp-PCR) has been recently 
considered from The US Centers for Disease Control and Prevention 
(CDC) as a valid diagnostic method along with the dark-field microscopy 
(DFM), which is still considered the reference test, despite its limits [13].  
Another group of tests useful for syphilis diagnosis is represented by 
serological tests which are in turn divided into “treponemal” tests, and non-
treponemal tests. 
Treponemal tests are based on the use of lyophilized T. pallidum or lysate 
of pathogenic T. pallidum to detect antibodies that are present in the sera 
of syphilitic patients and are specific for the bacterium. These tests 
comprise serum fluorescent treponemal antibody absorption test (FTA-
ABS) and microhemagglutination test for T. pallidum  (MHA-TP). 
Non-treponemal tests detect antibodies that are not specifically directed 
against the T. pallidum bacteria. These antibodies are produced by the 
body when an individual has syphilis but may also be produced in several 
other conditions. Examples of non-treponemal test are the Venereal 
Disease Research Laboratory (VDRL) and the Rapid Plasma Reagin 
(RPR) card test [14]. The latter test, for example, measures IgM and IgG 
antibodies to lipoidal material released from damaged host cells as well as 
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to lipoprotein-like material, and possibly cardiolipin released from the 
treponemes. 
The traditional approach for syphilis serodiagnosis utilizes a two step 
analysis: a first screening with a non-treponemal test followed by a 
confirmatory test based on a more specific determination. 
Serological diagnosis is widely available but it’s utility is affected by false-
positive results and by the need of equipped laboratories, [2]. 
After 60 years of use, penicillin remains the best pharmaceutical approach 
for the treatment of syphilis, though doxocycline and tetracycline can be 
also employed for efficient T. pallidum eradication (except for pregnant 
woman), in case of penicillin allergy. 
In the 1990s, azithromycin emerged as a particularly attractive alternative 
to penicillin therapy for syphilis. However, a study performed on T. 
pallidum isolated from patients in different USA countries and in Ireland, 
identified macrolide-resistant strains among these population.  
Several efforts have been devoted to the development of an effective 
potential vaccine. It has been demonstrated that the immunization of 
rabbits with some treponemal molecules (i.e. TpN15, TpN47, endoflagella) 
leads to the production of reactive antibodies, some having a great 
opsonic activity. Nevertheless, the protection against T. pallidum was only 
partial and resulted in an attenuation of the clinical manifestation of the 
disease and in a more rapid healing of lesions.  
Despite the fact that immunization induces a strong humoral immune 
response, the incomplete protection of the host suggests that a cell-
mediated immune response is critical for counteracting the infection and 
for clearing the bacterium. Moreover, the first targets of the immune 
response, represented by outer membrane proteins, are very rare in T. 
pallidum. For this reason, is clear that the identification of molecules on 
the surface of T. pallidum is essential for the development of an effective 
syphilis vaccine; their discovery and use in a multivalent vaccine will lead 
to the production of an effective vaccine for syphilis [1]. 
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1.2 Biology of Treponema pallidum 
Since it’s recognition in the 15th century as a new disease, syphilis has 
been subject of great mystery and legend. In the middle of 18th century 
John Hunter, an eminent Scottish physician and venereologist, in order to 
verify whether syphilis and gonorrhea were the same disease, inoculated 
himself with pus from an individual infected with a sexually transmitted 
disease. Unfortunately for Hunter, and also for the medical community, the 
patient was infected with the etiological agents of both the diseases: this 
caused decades of medical and scientific confusion. In 1838 Philippe 
Ricord, a French physician, published the results of some studies 
demonstrating that syphilis and gonorrhea were distinct infections 
[1](Lanfond & Lukehart, 2006). The etiology of syphilis remained unclear 
until 1905, when Schaudinn, a German parasitologist, examining a fresh 
preparation of a material provided by the dermatologist Erich Hoffmann 
from an eroded papula in the vulva of a woman with secondary syphilis 
[15], was able to discern a transparent, delicate spiral organism. The 
bacterium was named by Schaudinn and Hoffman  Spirochaeta pallidum  
because of the extraordinary difficulty in staining the organism; short time 
later Schaudinn proposed the name Treponema [16], [10].  
Nowadays is well established that the causative agent of syphilis is 
Treponema pallidum subsp. pallidum, a bacterium belonging to spiral-
shaped bacteria, the spirochaetaceae (the spirochetes), and related to 
other pathogenic treponemes that cause non-venereal diseases such as 
bejel, yaws, and pinta (Figure 7). A peculiar feature of T. pallidum, as well 
as of other spirochetes such as Borrelia burgdorferi (etiological agent of 
Lyme disease) and Leptospira interrogans (etiological agent of 
leptospirosis), is its ability to efficiently swim in a high viscous gel-like 
environment, such as connective tissue, where most of the flagellated 
bacteria are slowed or stopped. Motility is thought to play a pivotal role in 
widespread dissemination of spirochaetal infections and in establishing the 
chronic infection [14]. T. pallidum varies from 6 to 15 µm in length and is 
0.2 µm in diameter; the spiral-shaped body of T. pallidum is surrounded by 
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a cytoplasmic membrane, which is enclosed by a loosely associated outer 
membrane. A thin layer of peptidoglycan between the membranes 
provides structural stability. Endoflagella, organelles that allow for the 
characteristic corkscrew motility of T. pallidum, are located in the 
periplasmic space.  
T. pallidum has a small genome constituted by a single, circular 
chromosome of about 1.4 Mb containing approximately 1041 open reading 
frame (ORFs): a genome smaller than that of the majority of other 
bacteria. 
 
 
 
 
 
 
 
 
 
 
 
    Figure 7. T. pallidum on the surface  
     of a human lymphocyte [17] 
 
 
Probably due to the size of the genome, T. pallidum lacks genes that 
encode many metabolic functions. The bacterium is indeed able to carry 
out glycolysis but, on the same time, it lacks tricarboxylic acid cycle 
enzymes and an electron transport chain; pathways for the use of 
alternative carbon source for energy, for de novo synthesis of enzymes, 
cofactors and nucleotides are also absent. Despite the bacterium lacks 
pathways involved in amino acid and fatty acid synthesis, it possess 
enzymes for the interconversion of fatty acids and amino acids. The 
severe defect of biosynthetic pathways suggests that the bacterium 
acquires most essential macromolecules directly from the host, exploiting 
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interconversion pathways to generate others.  
An interesting aspect of the metabolism of T. pallidum is the absence of 
porin-like proteins, making unclear how nutrients can cross the outer 
membrane to gain the periplasmic space. Recent studies suggest that the 
presence of putative outer membrane proteins may alter the permeability 
of the outer membrane facilitating TM flux of hydrophilic solutes by the 
insertion of amphipathic α-helices into the external bilayer allowing non 
selective diffusion of nutrients into the periplasm [18].  
T. pallidum, human-obliged pathogen, does not survive outside the 
mammalian host, and the infectious capability is lost within few hours after 
its isolation. To obtain sufficient organisms for experimental manipulation, 
T. pallidum must be propagated in rabbit [19] and this represents the 
biggest obstacle to the syphilis research. The generation time of T. 
pallidum is unusually slow; it doubles in 30-33 h in vivo, and in 30-50 h in 
vitro. Several biological factors may contribute to the slow replication rate 
of T. pallidum.  
The organism, besides a weak ATP production, lacks enzymes such as 
catalase and oxidase that detoxify reactive oxygen species; for this reason 
the in vitro survival of T. pallidum is prolonged by low oxygen 
concentrations. In addition to its sensitivity to oxygen, T. pallidum also 
lacks the typical heat shock response regulated by σ32. The resulting 
heat lability may contribute to the slow growth of the organism [1].  
 
 
1.3 Treponema pallidum proteome 
Despite a severe lack of metabolic capabilities, sensitivity to oxygen, and 
decreased viability in an environment warmer than the body temperature, 
T. pallidum is able to invade and survive in a wide range of tissues and 
organs, causing chronic infection and a broad spectrum of clinical 
manifestation in the host. Moreover, the bacterium displays highly invasive 
capabilities: in rabbit infection, T. pallidum enters the bloodstream within 
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minutes after intratesticular or intradermal inoculation; similarly, organisms 
applied to rabbit genital mucosa are found in deeper tissues within hours 
[1]. These T. pallidum infectious capabilities relies on the presence of a 
wide range of bacterial proteins involved in many aspects of syphilis 
pathogenesis such as attachment to the extracellular matrix, motility and 
inflammation. 	  
The endoflagella of T. pallidum, responsible for its great motility in the 
host, are composed by multiple polypeptides arranged into an outer 
sheath and a central core [20]. Three proteins, FlaB1 (34,5 kDa), FlaB2 
(33 kDa) and FlaB3 (31 kDa) form the flagellar core which is covered with 
a sheath made up of subunits of the 37 kDa FlaA protein. FlaA subunits 
form chains, on the outer surface of the flagellum, which are attached to 
the flagellum central core [21]. Cell-mediated and humoral immune 
responses to endoflagella are induced during syphilis infection and most of 
the flagellar proteins are recognized by antibodies from both infected 
humans and rabbits. A peculiar feature of T. pallidum is that it lacks 
lipopolysaccharide (LPS), the typical endotoxin present on the surface of 
many gram-negative bacteria that causes inflammation and fever. On the 
other hand, mostly localized in the periplasmic space and probably 
released after Treponema autolysis [22], there are several lipoproteins 
endowed with pro-inflammatory activity that induce the expression of 
inflammatory mediators via toll-like receptor (TLR2) triggering. The 47-kDa 
lipoprotein TpN47 induces cultured endothelial cells expression of 
adhesion molecules such as ICAM-1, VCAM-1 and E-selectin, In 
accordance,, dermal injection of synthetic analogs of the TpN17 and 
TpN47 lipoproteins has shown to induce transient infiltration by PMNs, at 
the site of injection. Moreover TpN47 activates macrophages to express 
some pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, IL-8. TNF-α 
is also induced by TpN15, TpN17 and TpN38, whereas stimulation of 
macrophages with TpN17 activates IL-1β production [1]. 
The outer membrane of T. pallidum contains a very few number of 
proteins, if compared with other pathogens, and for this reason they are 
named Rare Outer Membrane Proteins (TROMPs) [20]. 
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The observation that only those treponemes that had been physically 
disrupted reacted with anti-T. pallidum antiserum, suggests that the 
surface of T. pallidum is non-antigenic and this permits the organism to 
evade the immune response [23]. 
 
 
1.4 TpF1 
TpF1, also known as TpN19, 4D antigen or TP1038, was one of the first T. 
pallidum proteins cloned in E. coli and is one of the best characterized. 
This protein has been identified and purified for the first time in the 1984 
[24]. It is a glycoprotein of 190 kDa, belonging to the Dps (DNA binding 
proteins from starved cells)-like proteins family and localized in the 
periplasmic space of the bacterium. The crystal structure of the protein 
was resolved for the first time in the 2006 by Thuminger and colleagues 
(Figure 8) [22]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Crystal structure of TpF1.(A) Van der Waals representation of the dodecamer 
of TpF1. Each subunit is colored differently. (B) Stereoview of the ribbon representation 
of TpF1 monomer [22]. 
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TpF1 is a dodecamer, about 90 Å in diameter, displaying 32 symmetry. 
Each subunit of the protein (19 kDa) folds in a way very similar to other 
mininferritins: a four-helix bundle, with helices B and C connected through 
a long stretch that includes a short helix. The deduced amino acid 
sequence contains two cysteine residues, which are presumably involved 
in interchain disulfide bonds whose reduction is required for the 
dissociation of the oligomeric structure [25]. Considering that disulfide-
bonded proteins have been demonstrated in the outer membranes of 
several bacteria pathogens, it has been suggested that TpF1 could fulfill a 
structural role in the outer membrane of T. pallidum [26]. However, in the 
1988 Cunningham and colleagues demonstrated that the protein derived 
from the periplasmic space  [27].  
The arrangement of the 12 monomers of TpF1 results in a nearly spherical 
shell typical of mininferritins, with an internal cavity where the iron is 
stored. TpF1 is highly immunogenic and specific antibodies were detected 
in about 95% of syphilitic sera by radioimmunoassay [28]; notably no 
antibodies against the 19 kDa monomer were found [24]. Immunogenic 
properties of the protein are difficult to rationalize on the basis of the 
crystal, and they may depend on the flexible N-terminal domain which 
protrudes from the surface of the spherical shell [22]. Recently, Babolin 
and colleagues have demonstrated that TpF1 activates the 
inflammasome, thus leading to the production of pro-inflammatory 
cytokines such as TNFα, IL-6 and IL-1β in human monocytes. Moreover, it 
has been demonstrated that TpF1 drives the development of T regulatory 
response that may, instead of being beneficial to the host, allow long-term 
persistence of the bacteria and contribute to the genesis and maintenance 
of the chronic disease [29].  
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1.3 The host immune response to T. pallidum 
The outcome of the T. pallidum infection depend on the duration and the 
site of the infection and on the immune status of the infected individual. 
Since the growth of T. pallidum is strictly dependent on the temperature 
(the internal temperature of the body is too high for optimal growth), the 
major combat zones consist in the external surfaces of the body, in which 
immune effector mechanisms try to annihilate a huge amount of 
proliferating bacteria. On the same time, lymphadenopathy or 
splenomegaly represent the evidence that an immune response develop 
also in the internal organs; clinical manifestations of the tertiary stage, 
such as granuloma, due to a chronic frustrated inflammation, reflects an 
inadequate immune response to a persistent infection [10]. 
Altought T. pallidum is a temperature sensitive bacterium, it has been 
reported that it quickly gains access to deeper tissues and the 
bloodstream [30]. Moreover the bacterium induces dermal cells to produce 
matrix metalloproteainase 1 [31], that, by degrading the matrix, may help 
the bacterium to penetrate tissues. 
Usually, polymorphonuclear cells (PMNs) are the first cells that infiltrate 
the site of infection. Accordingly, PMNs are seen in both experimentally-
induced and naturally-acquired early syphilis lesions, although infiltration is 
transient and the number of PMNs is low if compared with other acute 
bacterial infections; the inability of PMNs to adequately control T. pallidum 
is demonstrated by the progression of infection [1]. Another cell type 
present during the early stages of T. pallidum infection is represented by 
dendritic cells (DCs). Specialized DCs called Langerhans cells are found 
in the skin, which is site where lesions mainly develop during primary and 
secondary syphilis; DCs are also found in the mucosa, the intestinal wall, 
and the heart, all sites that can be infected by T. pallidum.  
Bouis and colleagues demonstrated that T. pallidum interacts with and is 
phagocytized by immature DCs, in vitro, promoting DCs maturation and 
leading to the production of pro-inflammatory cytokines such as 
interleukin-1β (IL-1β), IL-6, IL-12, and tumor necrosis factor alpha (TNF-α) 
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[32]. The production and secretion of pro-inflammatory cytokines 
significantly increases the immune response of the host enhancing 
endothelial cell activation, inflammatory cell migration, and promoting the 
maturation of immune system effectors. The activation of immune cells by 
T. pallidum is not likely to occur until treponemal antigens are released 
after bacterial distruption or autolysis [1]. Accordingly, the activation and 
maturation of DCs is delayed during T. pallidum infection, with respect to 
the time required in case of infection by other bacteria [32].  
Such a delay could contribute to the early dissemination of T. pallidum, 
giving organisms the opportunity to penetrate organs and tissues before 
an active inflammatory response has been mounted by the host [1].   
Of particular importance in the immune response against T. pallidum, is 
the strength of delayed-type hypersensitivity (DTH), which is mediated by 
CD4+ cells. DTH is a cell-mediated immune response, evoked since 
primary syphilis and characterized by an expanded population of antigen-
specific T cells that produce cytokines, activating and recruiting additional 
lymphocytes and macrophages. Macrophages accumulate at the site of 
infection and, once activated by CD4+ Th-1 cell, protect against infection 
by destroying and clearing the organism. The primary chancre is consider 
to be a DTH reaction that is extremely effective in clearing infectious 
organisms from the site of infection. On the other hand, when the DTH 
response is insufficiently effective, the bacterium is not completely 
eliminated giving rise to secondary and tertiary disease. In this condition 
high, persistent, localized antigenic challenge can lead to an excessive 
inflammatory response producing immunopathology in the form of 
granulomatous inflammation and tissue destruction [10]. In primary 
chancres, CD4+ T cells (helper) and macrophages predominate, whereas 
in the lesions of secondary syphilis CD8+ T cells (cytotoxic) are the most 
abundant cell type. The role of CD8+ T cells in the immune response to T. 
pallidum is still not deeply understood, however it has been suggested that 
CD8 T cells may play a role in the antisyphilitic host response through a 
IL-17- and IL-22-mediated antibacterial effector functions and IFN-γ–
dependent activation of macrophages involved in hte clearance of 
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opsonized treponemas. In addition, cytotoxic properties of CD8 T cells 
could be responsible for tissue destruction and inflammation 
characterizing the proggression of the disease [33]. 
Lesions of both primary and secondary syphilis are characterized by an 
abundant accumulation of Th1 cytokines such as IFN-γ  and TNF-α. It was 
found that cells of syphilitic patients are able to produce IL-2, IFN-g, TNF-
α, IL-10 and weakly IL-6 already in primary syphilis. The production of IL-6 
reaches highest level in secondary syphilis when slightly increases the 
ability of cells to secrete IL-10 reaching the highest value in early latent 
syphilis. The growing ability of Th2 cells to produce IL-6 and IL-10 is 
accompanied with a diminished production of IL-2, IFN-γ and TNF-α [34]. 
Soon after the onset of primary syphilis circulating antibodies against T. 
pallidum start to be detectable and they reach the maximum level during 
secondary stage of the disease, when the infection disseminates 
throughout the body. IgM antibodies are usually the first that are produced, 
but they are shortly followed by IgG. The antibody response is specific for 
a broad range of T. pallidum molecules, including lipids of the surface, 
flagellar proteins and lipoproteins [1]. 
Although effective immune response against treponemal infection is 
mounted by the host, the organism often manages to evade total 
eradication. In this regard, it has been recently shown that T. palldum is 
able to promote the development of T regulatory cells (Treg). These cells 
represent a subpopulation of T cells responsible for the down-modulation 
of the immune response [35], [29]. This could be considered as an 
additional strategy for the bacterium to avoid the elimination by the host 
thus contributing to the chronicity of the disease. 
 
 
1.5 Angiogenesis in syphilis disease 
The role of angiogenesis is well established in a number of pathological 
processes such as in benign and malignant tumors, but also in a variety of 
                                                                                   Introduction 
                                                                                                      
                                                                                             
	   30	  
infectious and inflammatory diseases. Nevertheless, the role of bacteria in 
inducing angiogenesis in chronic infections is still poorly understood. It is 
well established that T. pallidum activates the endothelium during the early 
stages of the disease and, during syphilis progression, it promotes new 
vessels formations, but the bacterial factors involved in this process are 
still unknown. In this regard, Macaron and colleagues [36] observed that 
the number of microvessels was significantly increased in cutaneous 
lesions of patients affected by secondary syphilis with respect of normal 
skin. Moreover, T. pallidum was shown to cause activation of endothelial 
cells inducing the expression of intercellular adhesion molecule-l (ICAM-1) 
and procoagulant activity on the surface of endothelial cells of human 
source (HUVECs), and promoting the adherence of lymphocytes and 
monocytes to endothelium exposed to T. pallidum [30]. Treatment of 
human endothelial cells with T. pallidum results in increased expression of 
the endothelial activation markers; interestingly this activation does not 
occur with non-pathogenic Treponema species. The angiogenic process 
observed in the early stages of the disease could be a mechanism 
exploited by the bacterium to uptake nutrients directly from the host and to 
disseminate throughout the whole organism. Increased vascular 
permeability is indeed one of the first stages in angiogenesis [37] and the 
organism could take advantage of the vascular leakage to access to and 
egress from the bloodstream, resulting in systemic spread.  
 
 
1.6 Angiogenesis 
1.6.1 Angiogenesis: an overview 
Angiogenesis (from the Greek word Angêion, vessel) is a 
physiopathological process involving the formation of new blood vessels 
and their subsequent growth, from a pre-existing vasculature. It occurs 
throughout life in both health and disease. A thick blood capillary network, 
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formed by angiogenic process, penetrates every metabolically active 
tissue in the body. Capillaries are crucial to ensure a correct and efficient 
exchange of nutrients and metabolites and they grow and regress in 
healthy tissues according to functional demands. Exercise stimulates 
angiogenesis in skeletal muscle and heart. A lack of exercise leads to 
capillary regression. Capillaries grow in adipose tissue during weight gain 
and regress during weight loss [38]. Leonardo da Vinci was the first to 
speculate about the cardiovascular system. His analytic method of the 
mechanism of organ formation was by analogy; he suggested that the 
vasculature developed like a tree from seed (the heart) by sprouting roots 
(the liver capillary network) and a trunk with major branches (aorta and 
arteries) (Figure 9) [39].  At the end of the 18th century John Hunter, the 
same Scottish scientist who studied syphilis pathogenesis [1], provided the 
first scientific insights in the field of angiogenesis. His observation, 
summarized in his Treatise published in 1794, suggested the existence of 
a relationship beetween vascularity and metabolic requirements [40]. A 
pioneer in the modern history of angiogenesis was Judah Folkman, a US 
oncologist: he formulated the hypothesis, included in a work published in 
1971, that the tumor growth is angiogenesis-dependent.  
 
 
 
 
 
 
 
 
 
 
Figure 9. Analogy between the botanic and the vascular tree as drawn by Leonardo da 
Vinci (taken from: ‘The anatomy of man: the cardiovascular system (ca. 1508)) [39] 
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The idea that the control of angiogenesis could lead to cancer therapies 
stimulated intensive research in the field with more than 5000 articles 
published within 40 years from 1970 to 2009 [38]. Nowadays is widely 
accepted that inhibiting angiogenesis can be therapeutic in cancer, 
ophthalmic conditions, rheumatoid arthritis, and many other diseases.  
Conversely, stimulation of angiogenesis can be beneficial in several other 
pathological conditions such as ischemic heart disease, peripheral arterial 
disease, and wound healing. 	  
 
1.6.2 The origin of blood vessels  
The presence of a system which ensures a suitable and functional 
exchange of oxygen, nutrients and metabolites in all the tissues of a 
multicellular organism, is fundamental for a correct development and, in 
general, for the life. In all animals, the cardiovascular system is the first 
organ system that develops in the embryo [39]. In this regard, two 
physiological processes play a critical role in the formation, maintenance 
and remodeling of the vascular network: vasculogenesis and 
angiogenesis. 
 
1.6.2.1 The origin of blood vessels: vasculogenesis 
Vasculogenesis is a process occurring only during the embryonic 
development, in the extra-embryonic and intra-embryonic tissues of 
embryos, and it can be defined as de novo formation of new blood vessels 
from angioblast. 
Angioblast are mesenchymal cells derived from hemangioblasts, 
multipotent cells, derived from mesodermal stem cells, which give rise to 
both hematopoietic stem cells, and angioblasts. Mesodermal-inducing 
factors belonging to the fibroblast growth factors family are crucial for the 
formation of both cell lines [39]. Angioblasts are a cell type with potency to 
differe
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characteristic markers of endothelial cells; the first blood vessels are the 
result of their differentiation  [41]. A first primitive proof of cardiovascular 
system appears in the middle of the third gestation week in human; 
angioblasts proliferate and coalesce into a primitive network of vessels 
known as the primary capillary plexus [42]. Once the latter is formed, 
further blood vessels are generated by angiogenesis, which are 
progressively remodeled into a functional adult circulatory system [39].  
 
1.6.2.2 The origin of blood vessels: angiogenesis 
Angiogenesis, consisting in the formation of new blood vessels from pre-
existing ones, occurs in the embryo, where it establishes a primary 
vascular network as well as an adequate vasculature for growing and 
developing organs. Nevertheless, angiogenesis occurs, occasionally, also 
in the adult for example in the regulation of female reproductive system 
and during repair processes such as in the healing of wounds and 
fractures [43]. This process is regulated by several vascular growth 
factors, such as the vascular endothelial growth factor family of proteins 
(VEGF). These act on specific receptors in the vascular system to 
stimulate the growth of new vessels. VEGF also promotes vascular 
permeability to water and to large proteins and vasodilatation [37]. 
Angiogenesis occurs through two different processes: sprouting 
angiogenesis and non-sprouting angiogenesis. Sprouting angiogenesis is 
characterized by sprouts composed of endothelial cells which usually grow 
in response to an angiogenic stimulus, such as VEGF. This process is 
characterized by the proteolytic degradation of the extracellular matrix, 
driven by a class of enzymes named matrix metalloproteinases, followed 
by chemotactic migration and proliferation of endothelial cells from pre-
existing vasculature (Figure 10) [39]. 
Sprouting angiogenesis is mainly induced by hypoxia condition; in poorly 
perfused tissues an oxygen sensing mechanism promotes the formation of 
new blood vessels in order to ensure a correct metabolic supply to 
parenchymal cells. 
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Figure 10. Schematic representation of VEGF-drived angiogenesis [38] 
 
 
Many types of parenchymal cells such as monocytes, hepatocytes, and 
neurons respond to a hypoxic environment by secreting VEGF [44]. 
When the local tissue receives adequate amounts of oxygen, the 
concentration of VEGF returns to the basal level and this promotes the 
maturation and stabilization of the capillary [38]. 
Vessel maturation and stabilization require also the recruitment of 
pericytes and the deposition of extracellular matrix along with shear stress 
and other mechanical signals [42].  
Non-sprouting, or intussuspective angiogenesis, discovered in post-natal 
lungs of rats and humans in 1986 [45], has a prominent role in vascular 
development in embryos and in the formation of artery and vein 
bifurcations.       
 
 
Figure 11. Schematic representation of non-sprouting angiogenesis [46] 
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This process starts with the migration of opposing endothelial walls within 
a vessel, followed by rearrangements of interendothelial junctions and 
invasion of pericytes and myofibroblasts, consequently leading to the 
splitting of the vessel (Figure 11) [46]. 
Non-sprouting angiogenesis is promoted by pro-angiogenic agents, such 
as VEGF, but also by mechanical stresses induced by the blood flow in 
some high-flow regions of the circulation [42]. Both types of angiogenesis 
are thought to occur in virtually all tissues and organs. 
 
 
1.5.4 Angiogenesis: mechanisms of regulation 
Angiogenesis is a fundamental and highly regulated biological process, 
not only in physiological conditions, but also in a number of disease 
including cancer, diabetic, retinopathy and rheumatoid arthritis. 
Angiogenesis is tightly regulated and depends on the balance between 
different molecules ; specific angiogenic molecules can initiate the process 
and specific inhibitory molecules can stop it. Angiogenic factors and 
inhibitors have been discovered in the past two decades and the 
mechanism by which they regulate the process remain to be fully 
understood. Several inducers of angiogenesis have been identified, 
including the members of the VEGF family, angiopoietins, transforming 
growth factors (TGF), platelet-derived growth factor (PDGF), tumor 
necrosis factor-α, interleukins and the members of the fibroblast growth 
factor (FGF) family [47]. 
VEGF is a major angiogenic factor that regulates several endothelial cell 
functions, including mitogenesis, permeability, vascular tone and the 
production of vasoactive molecules [48]. Vascular endothelial growth 
factor-A (VEGF-A) is the best characterized and the most studied of the 
VEGF family members. VEGF-A exerts its biologic activity through the 
interaction with transmembrane tyrosine kinase receptors including the the 
neuropilin receptors (NP-1 and NP-2), expressed on neurons and vascular 
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endothelium, VEGF receptor-1 (VEGFR-1) and VEGFR-2, both expressed 
on vascular endothelial cells [49]; however VEGFR-2 appears to be the 
major receptor responsible for mediating the pro-angiogenic effects of 
VEGF-A. VEGF-A is the most potent pro-angiogenic factor identified so 
far. The engagement of VEGFR-2 triggers a phosphorilation cascade 
culminating in proliferation, sprouting and tube formation of endothelial 
cells. In addition, VEGF-A promotes vasodilatation by inducing the 
endothelial nitric oxide synthase, resulting in the nitric oxide production 
[47].  
Angiopoietins 1 and 2 (Ang1 and Ang2) belong to a family of 70-kDa 
secreted proteins that promote maintenance, growth and stabilization of 
the vessels [47], [42].  
Acidic and basic fibroblast growth factors (aFGF and bFGF, respectively) 
are heparin-binding proteins that trigger many processes involved in 
angiogenesis such as endothelial cell proliferation and MMPs production, 
following the engagement of tyrosine kinase FGF receptors (FGFRs). 
Nevertheless, unlike VEGF, which is mitogenic primarily for endothelial 
cells, FGF stimulates proliferation of most cells derived from embryonic 
mesoderm and neuroectoderm including pericytes, fibroblasts, myoblasts, 
chondrocytes, and osteoblasts.  
The role of PDGF in angiogenesis is not yet fully understood [47], however 
it probably plays a role in recruiting pericytes to preformed capillaries or in 
inducing the proliferation of pericytes previously recruited by a PDGF-
independent mechanism, thus helping the maintainance of capillary wall 
stability [42].  
Conversely, the transforming growth factor-β (TGF-β) possesses both pro- 
and anti-angiogenic properties. In particular, at low doses, TGF-β1 seems 
to have pro-angiogenic activity by up-regulating angiogenic factors and 
proteinases, whereas, at high doses, TGF-β1 inhibits the proliferation of 
endothelial cells promotes basement membrane reformation and 
stimulates the differentiation and recruitment of smooth muscle cells [47]. 
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1.5.4.1 IL-8: a pro angiogenic chemokine  
In addition to the classical angiogenesis promoters, also some pro-
inflammatory molecules are known to exert pro-angiogenic activities such 
as TNFα, IL-1β and chemokines of the CXC family. 
Inflammation and angiogenesis are linked processes, but the precise 
relationship existing has not been well understood [50]. 
Chemokines are multifunctional mediators mainly responsible for 
leukocyte recruitment to inflamed tissues. Chemokines of the CXC family, 
however, have also a pivotal role in the control of angiogenesis: 
accordingly, not only leukocytes but also endothelial cells express specific 
receptors for these molecules [51].  
IL-8, also known as CXCL8, is a pro-inflammatory CXC chemokine that 
promotes neutrophil chemotaxis and degranulation. Moreover, it is widely 
accepted that this chemokine plays also a crucial role in modulating 
angiogenesis by interacting directly with endothelial cells [52].  
 
 
 
Figure 12. IL-8 signaling pathways. The schematic diagram illustrates the signaling 
pathways activated after the engagement of CXCR1and/or CXCR2 receptors with IL-8 
[53]. 
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IL-8 gene expression is regulated by several transcription factors (Figure 
12): the activator protein 1 (AP1), the nuclear factor-κB (NF- κB) and the 
cAMP response element-binding protein (CREB) [53], [54]. 
IL-8 exerts its biological function through the engagement of two cell-
surface G protein-coupled receptors known as CXCR1 and CXCR2. 
Signals are transmitted across the membrane through a ligand-induced 
conformational change that promotes the coupling to functional 
heterotrimeric G proteins. The activation of the G protein triggers a 
phosphorylation cascade culminating in the activation of several effectors, 
including the primary effector phosphatidil-inositol-3-kinase (PI3K), the 
phospholipase C (PLC) and/or the mitogen associated protein kinases 
(MAPK). 
Furthermore, IL-8 signaling activates members of the RhoGTPase family, 
and a number of non-receptor tyrosine kinases involved in the regulation 
of cytoskeleton dynamics (Figure 12) [53]. Through the activation of these 
different signaling pathways, IL-8 promotes endothelial cell proliferation 
and migration as well as the production of matrix metalloproteinases such 
as MMP2 and MMP9. Recent studies also reveals that IL-8 inhibits 
spontaneous apoptosis of endothelial cells and modulate anti- and 
proapoptotic gene expression such as Bcl-2, Bcl-xL, Bcl-xs, and Bax [52].  
 
 
 
                                                                                    Material and Methods 
                                                                                                      
                                                                                             
	   39	  
Materials and Methods 
1.Reagents 	  
TpF1 was produced as described below; human umbilical vein endothelial 
cells (HUVECs) were isolated as described below; HEPES, human 
endothelial serum-free medium (HE-SFM), Fast DiI, Phalloidin-Alexa Fluor 
546, rhodamine-labelled 10 kDa-dextran, Trizol Reagent, Superscript II, 
MMLV reverse transcriptase and protease inhibitor cocktail were from Life 
Technologies (Glasgow, Scotland, UK); Medium 199 (M199), foetal bovine 
serum (FBS), heparin, forskolin, LPS, NBT, BCIP, FITC-labeled 70 kDa-
dextran, Tricaine and 1-phenyl-2-thiourea were from Sigma-Aldrich (St. 
Louis, MO, USA); L-glutamine, trypsin-EDTA, penicillin-streptomycin, were 
from Euroclone (Siziano, Italy). Fibronectin was from Roche (Basel, 
Switzerland). Matrigel was from Becton, Dickinson & Company (Franklin 
Lakes, New Jersey, USA). Goat anti-human IL-8 blocking antibody was 
from Abcam (Cambridge, UK); human recombinant VEGF was from 
Immunological Sciences (Roma, Italy). Monoclonal antibody anti anti-actin 
(clone C4), KG501 and QNZ were from Millipore (Bedford, MA, USA); 
rabbit policlonal antibodies anti-phospho-CREB (ser133) and anti-
phospho-p65 were from Cell Signalling Technology (Danvers, MA, USA); 
Collagenase was from Worthington (Lakewood, NJ, USA). 
 
 
2.2 Bacterial strains 
 
Escherichia coli Top10 strain was used for cloning TpF1 gene. Bacillus 
subtilis SMS118 strain was used for expression and purification of TpF1 
protein.  
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2.3 Construction of the plasmid pSM214G-tpf1  
 
TpF1 was cloned and expressed in E. coliXl1blue. TpF1 gene was 
amplified by PCR starting from a preparation of Treponema pallidum 
genome. The PCR reaction was carried out using standard method.  
 
The thermal cycling parameters were as follows:  
 
• Initial denaturation: 94°C for 5 min 
• Denaturation: 94°C for 1 seconds 
• Annealing: 50° C for 1 seconds 
• Extension: 72°C for 45 seconds 
• Final extention: 72°C for 10 min 
 
Primers used were:  
 -Forward 5'-ccggaattcacgatgaacatgtgtaca-3'  
 -Reverse: 5'-cccaagcttctaggctttcagggtagc-3' 
 
Primers contain restriction site for EcoRI and HindIII, respectively. The 
amplified fragment was excised by digestion with EcoRI and HindIII and 
ligated into EcoRI and HindIII sites of the expression vector pSM214G. 
pSM214G contains an artificial constitutive promoter, a chloramphenicol 
resistance cassette, and two origins of replication that allow expression of 
cloned genes both in E. coli and in B. subtilis. 
 
2.4 Transformation of competent Escherichia coli 	  
Top10 chemically competent cells (Invitrogen) which have been kept on 
freezer storage were thawed on ice. 100-200 ng of plasmid DNA were 
added to the competent cells and the transformation mix was kept on ice 
for 30 min. The cells were heat-shocked for 30-40 sec at 42°C and the 
cooled on ice for 2-3 min. The cells were incubated for 45 min at 37°C in 
500 µl of Luria-Bertani (LB) broth (10 g/l Bacto Tryptone, 5 g/l Bacto yeast 
For 45 cycles 
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extract, 10 g/l NaCl) in agitation. The mix was plated on LB agar plates 
which contained the antibiotic chloramphenicol (20 µg/ml) that selects for 
transformants. The plates were incubated overnight at 37°C. Bacterial 
colonies were colony-PCR analyzed. 
 
 
2.5 Plasmid DNA isolation from bacteria (Miniprep) 	  
E. Coli cells carrying the plasmid of interest were incubated overnight at 
37°C at constant shaking (200-220 rpm) in 5 ml of LB broth supplemented 
with the appropriate antibiotic (chloramphenicol 20 µg/ml). The cells were 
harvested by centrifugation at 13,000 x g (microcentrifuge Biofuge, 
Haeraeus) for 3 min and the plasmid DNA was isolated using the QIAprep 
Spin miniprep kit (Qiagen) following the manufacturerʼs instruction. Briefly, 
cellular pellet was resuspended in 250 µl of buffer P1 (Qiagen), then were 
added 250 µl of buffer P2 (Qiagen) and the suspension was gently 
inverted 2-3 times; 350 µl of neutralizing buffer N3 (Qiagen) were added, 
the suspension was gently inverted and centrifuged 10 min at 13,000 x g. 
Supernatants were applied in the Qiaprep spin column and centrifuged 1 
minute at 13,000 x g; the column was washed two times by adding 750 µl 
of buffer PE (Qiagen) and centrifuged 1 minute at 13,000 x g. The purified 
plasmid DNA was eluted from the column with 50 µl of sterile water. The 
concentration and quality of the purified DNA was measured with a UV 
spectrophotometer at OD 260-280. 
 
 
2.6 Bacillus subtilis transformation 	  
Bacillus subtilis cells were chemically competent induced for the 
electroporation. Bacillus subtilis was grown overnight at 180 rpm at 37°C 
in 10 ml of LB broth; 1% of this culture was then grown 3 h at 150 rpm at 
37°C in 50 ml of LB broth (to an OD of 0,6). Bacteria were centrifuged 10 
min at 1,000 x g and washed two times with Hepes 1 mM 10 min at 1,000 
x g. Cells were then treated two times with electroporation buffer (Hepes 1 
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mM pH 7.0, PEG 8000 25% v/v, mannitol 0.1 M). Bacteria were 
resuspended in 250 µl of electroporation buffer to a final OD of 1.9. The 
bacteria were aliquoted in 70 µl. Bacillus subtilis (70µl) was electroporated 
using 1.5 µg of DNA; one pulse of 200 Ω, 2.3 κV, 2.5 µF. Electroporated 
cells were incubated 10 min at 25°C in 500 µl of LB and then incubated 2 
h and 30 min at 37°C under slow agitation (at 120-140 rpm). The bacteria 
were plated on LB-agar plate supplemented with of chloramphenicol (20 
µg/ml) and incubated for 20 h at 37°C. 
 
 
2.7 TpF1 purification 	  
B. subtilis strain SMS 118 containing the plasmid pSM214G-TpF1 was 
grown for 15 h in 500 ml of YT medium (15 g/l yeast extract, 16 g/l 
bactotryptone, 5 g/l NaCl) supplemented with chloramphenicol (20 µg/ml). 
The cells were pelleted by centrifugation at 4,000 x g and resuspended in 
10 ml of fresh Tris-HCl 30 mM, pH 7.8 plus protease inhibitors (Roche). 
After three passages through a French Press and removal of debris by 
centrifugation at 32,000 x g, powder ammonium sulphate was added to 
the supernatant to a final concentration of 12.5 % w/v, at 4°C. At this 
percentage of ammonium sulfate most of the protein remained in solution. 
After 3 h at 4°C at slow stirring the sample was centrifuged at 32,000 x g 
for 30 min, the supernatant was recovered and ammonium sulfate was 
added to a final concentration of 22.5% w/v. The sample was kept for 3 h 
at at 4°C at slow stirring and then centrifuge at 32,000 x g for 30 min. The 
pellet containing the protein TpF1 was suspended in NaCl 0.1 M, Tris 30 
mM, DTT 5 mM, pH 8.4 (buffer A) and dialyzed overnight in buffer A. The 
sample was fractionated by ion-exchange chromatography using a MonoQ 
column (Amersham Biosciences) equilibrated with buffer A. After the 
sample was applied, the column was eluted with a linear NaCl gradient in 
Tris 30 mM, DTT 5 mM, pH 8.4. Fractions were analysed by SDS-PAGE 
and TpF1-containing fractions were pooled. TpF1 was further purified by 
gel filtration chromatography using a superdex 200 HR 10/30 column 
(Amersham Biosciences) equilibrated with phosphate buffer saline, pH 
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7.8. Protein was concentrated using the ultrafiltration system Centricon® 
(Millipore), and the final product was checked for purity in a Comassie 
brilliant blue stained gel and analyzed by western blot with a specific 
polyclonal antibody. 
 
 
2.8 Endothelial cell isolation 
 
Human umbilical vein endothelial cells (HUVECs) were isolated from 
human cord of healthy donors. Cords were laid on a clean dish, excess 
blood was dabbed off and fresh cuts were made on both of the ends. The 
umbilical veins were cannulated with sterile cannulas; a cord has one vein 
and two arteries, usually the vein is the largest opening while the two 
smaller ones are arteries. Cannulas were clamped in place with a string 
and 20cc syringes were attached to each cannula. The vein was then 
perfused with phosphate buffered saline (PBS) using the syringe to wash 
out the excess of blood; the washings were performed until all the blood 
present in the vein was eliminated. The waste was collected in a beaker 
with bleach. Once cleaned the vein, about 10-12 ml of a 55 U/ml 
collagenase solution was poured inside a syringe and then pushed into the 
vein until the exit of a first amount from the opposite end. The cord was 
incubated for 20 minutes at 37°C, 5% CO2. After 15 minutes, the cord was 
gently massaged with hands and then relocated into the incubator for the 
remaining time. After incubation the collagenase solution containing 
endothelial cells was flushed from the cord by perfusion with a wash 
medium (M199 20% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin) for 
a total volume of 50 ml. The effluent is collected in a sterile 50-ml tube. 
The cells were centrifuged 7 minutes at 100 G then medium was 
discarded, and endothelial cells were resuspended in 5 ml of fresh culture 
medium (described above). The cell suspension was placed in 25-cm flask 
coated with 2% gelatine and incubated over night at 37° C, 5% CO2. 
Next day the supernatant was removed, cells washed with PBS and then 
replaced with fresh medium. 
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2.9 Endothelial cell culture  	  
HUVECs were kept in culture in 2% gelatin-coated cell culture flasks, in 
medium 199 supplemented with 20% foetal bovine serum (FBS), 50 µg/ml 
heparin, 100 U/ml penicillin, 100 µg/ml streptomycin, 68 µM L-glutamine, 
10 mM Hepes and 20 ng/ml epithelial growth factor (EGF). Cells were 
used at passage 2–5 for all experiments. In all experiments stimuli were 
added in human endothelial serum free medium (HE-SFM) without any 
supplement. 
 
2.10 Proliferation assay  	  
HUVECs were seeded in 2% gelatin-coated 96-well tissue culture plate at 
1×104 cells/well and maintained in M199 complete medium for 2 h before 
the application of stimuli in HE-SFM.  Cells were exposed to 1 µM TpF1 or 
20 ng/ml VEGF or vehicle (saline). For the inhibition experiments, cells 
were pre-treated or not with 1 µg/ml anti-IL-8 blocking antibody that was 
maintained during TpF1 treatment. After 12 and 24 h, cells were harvested 
and counted with electronic Coulter counter (Beckman Coulter). The 
proliferation rate is reported as the fold increase in cell number with 
respect to the number of plated cells. 
 
2.11 Migration assay 	  
Cell migration was evaluated by Transwell migration assay coating the 
lower side of the polycarbonate filter (8 µm pores) with fibronectin (5 
µg/cm2). Fast DiI labelled HUVECs (2 × 105 cells) were added to the upper 
compartment in HE-SFM and 1 µM TpF1 or 20 ng/ml VEGF, used as 
positive control, were added to the lower compartment. For the inhibition 
experiments supernatant of HUVECs, grown to confluence and stimulated 
in HE-SFM with 1 µM TpF1 for 24 h, was pre-incubated with 1 µg/ml anti-
IL-8 blocking antibody for 45 min at 37°C before adding to the to the lower 
compartment. Migrated cells were quantified after 2 h, 6 h and 24 h by a 
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microplate reader (Infinite 200, Tecan), comparing to a standard curve and 
expressed as % of seeded cells. 
 
2.12 In vitro tube formation 
 
5.5 × 104 HUVECs, seeded on wells coated with Matrigel (12 mg/ml), were 
incubated for 10 h with 1 µM TpF1, in presence or absence of 1 µg/ml 
anti-IL-8 blocking antibody, to allow tube formation. VEGF was used as 
positive control. After fixation with 4% paraformaldehyde and staining with 
Phalloidin-Alexa Fluor 546, tubes (capillary-like structures) were counted 
under Leica AF6500 microscope using a LAS software (Leica).  
 
 
2.13 Real-time PCR analysis on Endothelial cells 	  
HUVECs were seeded in 2% gelatin-coated 24-well tissue culture plate at 
4×104 cells/well and maintained in M199 complete medium until they 
reached 80% confluence. Cells were stimulated with 1 µM TpF1 in HE-
SFM, harvested, and total RNA was isolated using RNeasy Kit according 
to the manufacturer’s instructions (Qiagen, Venlo, Netherlands). RNA was 
reverse-transcribed using Superscript II and cDNA was amplified with the 
following protocol:  
 
Sample mix was prepared as follows: 
 
 
 
 
 
 
 
 
Power SYBR Green PCR Master Mix 5 µl 
Primer Forward 50 µM 0.18 µl 
Primer Reverse 50 µM 0.18 µl 
H2O  2.64 µ 
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The PCR cycle for the Real-Time PCR was: 
• Initial denaturation: 95°C for 15 min 
• Denaturation: 95°C for 15 seconds 
• Annealing: 58° C for 20 seconds 
• Extension: 72°C for 10 seconds 
 
 
 
The primers used for Real-time PCR analysis were the following: 	  
Gene	   	  	   	  Primer	  sequence	   AT	  (C°)	  
18S	   	  F	  	   5′-CGGCTACCACATCCAAGGAA-3′	   58	  	  	   R	   5′-GCTGGAATTAGCGCGGCT-3’	   	  	  
VEGF-A	   	  F	   5′-GCCTTGCCTTGCTGCTCTA-3′	   58	  	  	   	  R	   5′-GATGTCCACCAGGGTCTCG-3′	   	  	  
IL-8	   F	   5′-TTGGCAGCCTTCCTGATT-3′	   58	  	  	   R	   5′-AACTTCTCCACAACCCTCTG-3′	   	  	  
 
 
After amplification, data analysis was performed using the second 
derivative algorithm by applying the 2−ΔΔCT method. For each sample, data 
were normalized to the endogenous reference gene (ribosomal subunit 
18S). Cells harvested at time zero were taken as the reference value, set 
to 1 AU (arbitrary unit, as shown in the figures), and the relative 
expression levels for treated or untreated cells were calculated and 
shown. 
 
2.14 ELISA 	  
Culture supernatants of HUVECs, harvested for quantification of mRNAs, 
were collected and stored at -80°C for subsequent quantification of 
cytokine content by ELISA: specific kits for IL-8 (Affymetrix, High 
Wycombe, UK) and VEGF-A (Raybiotech, Norcross, GA, USA) were used 
For 45 cycles 
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following the manufacturers’ instructions. When required, cells were pre-
incubated for 30 min with 100 nM KG501 or 10 µM QNZ before the 
exposure to TpF1. 
 
2.15 Evaluation of the phosphorylation state of CREB and 
NF-κB p65 subunit 	  
HUVECs were seeded in 2% gelatin-coated 6-well tissue culture plate at 
3×105 cells/well and maintained in M199 complete medium until they 
reached 80% confluence. Cells were washed with HE-SFM and incubated 
in the same medium with 1 µM TpF1, 25 µM forskolin, 1 µg/ml LPS or 
saline for 30 min. Cells were then washed with ice-cold PBS, lysed in 1% 
Triton X-100, 20 mM Tris-HCl pH 8.0, 150 mM NaCl in the presence of 
protease inhibitor cocktail, resolved by SDS-PAGE and transferred to 
nitrocellulose. Phospho-proteins were revealed by specific policlonal 
antibodies. After band densitometry, actin was used to normalize the 
amount of the phospho-proteins. 
 
2.16 Whole cell ELISA 	  
HUVECs were seeded in 2% gelatin-coated 96-well tissue culture clear-
bottom black plate (R&D Systems, Minneapolis, MN, USA) at 1×104 
cells/well and maintained in M199 complete medium until they reached 
80% confluence. Cells were exposed for 5, 15, 30 and 60 min to 1 µM 
TpF1, 1 µg/ml LPS, 25 µM forskolin or vehicle (saline) in HE-SFM. 
Phosphorylation of CREB on serine 133 and phosphorylation of IkB-α on 
serine 32 and 36 were evaluated by whole-cell ELISA according to the 
manufacturer’s instructions (R&D). For each sample, data were 
normalized to the total CREB protein or to the GAPDH protein in case of 
IkB-α. Normalized fluorescence value of cells at time 0 was taken as 
reference and set as 1; CREB and IkB-α phosphorylation of treated cells 
was expressed as fold change with respect to the time 0.  
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2.17 Fluorescence Resonance Energy Transfer Imaging 	  
HUVECs (5 × 105 cell/well), seeded on 24 mm diameter gelatin-coated 
coverslips in M199 complete medium 20% FBS, were transfected with 1 
µg of mammalian expression plasmid encoding the cAMP biosensor 
Epac1-camps [55], using Amaxa Nucleofector Technology according to the 
manufacturer’s instructions (Basic Nucleofector Kit for Primary Endothelial 
Cells, Lonza, Basel, Switzerland). FRET imaging experiments were 
performed 24–48 h after cell transfection. HUVECs were maintained at 
37°C in HEPES-buffered Ringer-modified saline (125 mM NaCl, 5 mM 
KCl, 1 mM Na3PO4, 1 mM MgSO4, 2 mM CaCl2, 5.5 mM glucose and 20 
mM Hepes, pH 7.4) and imaged with an inverted microscope (Olympus 
IX50) equipped with a CellR imaging system and a beam-splitter optical 
device (Multispec Microimager; Optical Insights). Images were acquired 
every 5 s with a 603, 1.4 NA oil-immersion objective (Olympus) using the 
CellR software and processed using ImageJ (http://rsb.info.nih.gov/ij/). 
FRET changes were measured as changes in the background-subtracted 
480/545 nm fluorescence emission intensities upon excitation at 430 nm 
and expressed as DR/R0, where R is the ratio at time t and R0 is the ratio 
at time = 0 s; DR = R-R0. 
 
2.18 Zebrafish embryos  	  
All experiments, approved by the Ethical Committee of the University of 
Padua, were performed at the larval stage of zebrafish. Zebrafish (Danio 
rerio) embryos were obtained from natural spawning of wild-type and the 
transgenic zebrafish, Tg (Fli: eGFP) strain [56]. Embryos were raised and 
fishes were maintained as described [57]. Embryos were treated with 1-
phenyl-2-thiourea to inhibit pigment formation [57]. This treatment regimen 
did not appear to have a significant effect on vascular development. For 
TpF1 injection, anesthetized living embryos at 2 dpf were first embedded 
in low-melt agarose in order to hold it in place. Embryos were injected via 
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glass capillaries into the yolk extension or the caudal artery with 10 µM 
TpF1, under a dissecting stereomicroscope and were allowed to develop. 
Control embryos were injected with the tracer and saline (vehicle). Larvae 
at 4 dpf were photographed live using a Nikon C2 H600L confocal 
microscope with water dripping objectives. Laser used to excite 
fluorophore was 488 nm for eGFP. The total volume and the intensity of 
fluorescence of vessels was calculated using VOLOCITY 6.0 software 
(Perkin Elmer, Waltham, MA) on eGFP-positive confocal acquired images. 
Embryos and larvae were anesthetized using Tricaine and mounted in 
0.8% low melting agarose on a glass lid before photographing. Statistical 
analyses to compare results for injected samples and controls were 
performed using uncoupled Student’s two-tailed t-test and Prism 
GraphPad software package. 
 
2.19 RNA Isolation and real-time PCR in zebrafish 
 
A group of 30 larvae were injected at 2 dpf into the yolk extension with 10 
µM TpF1 and a second group of 30 larvae were injected with saline 
(vehicle). At 4 dpf, RNAs were extracted from the larvae of each group, 
using Trizol Reagent, and pooled. One microgram of total RNA was 
reverse transcribed using MMLV reverse transcriptase and cDNA was 
amplified with the following protocol:  
 
The PCR cycle for the Real-Time PCR was: 
• Initial denaturation: 95°C for 15 min 
• Denaturation: 95°C for 15 seconds 
• Annealing: 60°C for 20 seconds 
• Extension: 72°C for 30 seconds 
 
 
 
 
For 45 cycles 
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The primers used for Real-time PCR analysis were the following: 
 
Gene	   	  	   	  Primer	  sequence	   AT	  (C°)	  
β-actin 	   	  F	  	   5’-CAGCAAGCAGGAGTACGATGAGT-3’	   60	  	  	   R	   5’-TTGAATCTCATTGCTAGGCCATT-3’	   	  	  
IL-8 a	   	  F	   5’-AGCTTGAGAGGTCTGGCTGTAGA-3’	   60	  	  	   	  R	   5’-CGAGGCGTTGATAAGCTCTCTGCT-3’	   	  	  
IL-8 b	   F	   5’-TGTTTTCCTGGCATTTCTGACC-3’	   60	  	  	   R	   5’-TTTACAGTGTGGGCT TGGAGGG-3’	   	  	  
VEGF-A	   F	   5’-GATGTGATTCCCTTCATGGATGTGT-3’ 60	  	  	   R	   5’-GGATACTCCTGGATG ATGTCTACCA-3’ 	  	  
 
After amplification, data analysis was performed using the second 
derivative algorithm by applying the 2−ΔΔCT method. For each sample, data 
were normalized to the endogenous reference gene (β-actin). Vehicle-
injected larvae were taken as the reference value, set to 1 AU (arbitrary 
unit, as shown in the figures), and the relative expression levels for treated 
larvae were calculated and shown. 
 
2.20 Vessel visualization 	  
For yolk vessel observation, embryos were injected at 1 dpf into the yolk 
extension with 10 µM TpF1, or saline and 3 dpf, the embryos were fixed in 
4% paraformaldehyde (PFA) and stained for endogenous alkaline 
phosphatase activity. Briefly, embryos were fixed in 4% PFA for 2 h at RT 
and washed 5–6 times in PBS 0.1% Tween-20 (PBST). Embryos were 
dehydrated and made permeable by successive washes in 25, 50, and 
75% methanol (MeOH) in PBST, and finally suspended in 100% MeOH. 
This was followed by serial rehydration of the embryos in 75, 50, and 25% 
MeOH in PBST and suspended in PBST. Embryos were equilibrated with 
alkaline phosphatase buffer (100 mM Tris, pH 9.5, 50 mM MgCl, 100 mM 
NaCl and 0.1% Tween-20) at RT. Subsequently they were incubated in 
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staining solution (335 µg/ml NBT and 175 µg/ml BCIP in alkaline 
phosphatase buffer). Staining reaction was stopped by adding PBST. 
Embryos were immersed in a solution of 5% formamide and 10% 
hydrogen peroxide in PBS for 20 min to remove endogenous melanin in 
the pigment cells, allowing the visualization of the yolk vessels and stored 
in 80% glycerol in PBST for further analysis. 
For the visualization of caudal vessel, 3 dpf embryos were anesthetized 
with 0.003% Tricaine and microangiografy was performed. A solution of 
FITC-labeled 70 kDa-dextran was injected into the cardiac venous sinus 
and images of live fishes were generated using a Leica inverted 
microscope connected to a Leica DFC490 camera.  
The length of the vessel and the ectopic processes in the yolk and the 
distance from CA (caudal artery) and CV (caudal vein) were measured 
using Sigma Scan Pro software. 
 
2.21 Statistical analysis 	  
Data are reported as the mean ± S.D. Student t test was used for 
statistical analysis of the differences between experimental groups. The p 
values ≤ 0.05 were considered significant. 
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Results 
 
Syphilis is a progressive and multistage disease with diverse and wide-
ranging manifestations. How the bacterium triggers the clinical 
manifestations characterizing the different stages of the disease has not 
been fully elucidated; however it is established that T. pallidum is able to 
invade and survive in a wide variety of tissues and organs [1] and that it 
promotes the formation of new blood vessels [36]. Angiogenesis could 
have a crucial role in syphilis pathogenesis, at least for two reasons: i) the 
bacterium has limited metabolic capabilities [58], thus probably it requires 
support from the host and it may derive most essential macromolecules 
from the blood. ii) Increased vascular permeability is one of the first stages 
in angiogenesis [37] and the organism could take advantage of the 
vascular leakage to access to and egress from the bloodstream, resulting 
in systemic spread.  
Although syphilis is a highly inflammatory disease, is well established that, 
in untreated patient, it becomes chronic and this probably reflects the 
ability of the bacterium in eliciting a T regulatory response, which could be 
associated with fading of the host effector immune responses against the 
pathogen [59], [60]. In this regard, it has been recently demonstrated in 
our lab that the bacterioferritin TpF1, a major antigen of T. pallidum, in 
addition to promote the secretion of proinflammatory cytokines via 
inflammasome, it has a central role in driving this suppressive immune 
response, by modulating the development of regulatory T cell [29]. 
TpF1 is a protein structurally related to another immunomodulant antigen 
produced by Helicobacter pylori and called HP-NAP. Both these proteins 
belong to the Dps-like family, a versatile group of bacterial stress 
miniferritins with a nearly spherical dodecameric structure.  
HP-NAP, besides interacting with neutrophils, monocytes and dendritic 
cells and modulating their activity (as TpF1 does), also binds to endothelial 
cells, in which it is internalized by transcytosis at the basal side before 
being exposed on the surface exposed to the lumen of blood vessels. 
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Considering the pivotal role of TpF1 in syphilis pathogenesis, the 
homology existing between HP-NAP and TpF1, and the fact that the 
angiogenic process is a hallmark of the secondary syphilis, we wondered 
whether TpF1 could interact with endothelial cells and promote new blood 
vessels formation. 
To investigate the angiogenic activity of TpF1 we took advantage of in 
vitro assays using human humbelical vein endothelial cells (HUVECs) as 
cell model. The majority of assays on endothelial cell utilize HUVECs, 
because they are easy to obtain and manipulate and because they 
maintain the capacity to proliferate preserving, on the same time, their 
normal in vivo physiological characteristics. 
However, endothelial cells are highly heterogeneous (depending on the 
blood vessel type, organ, host) in vivo and they are mostly in a quiescent 
state of the established vasculature rather than in a proliferative state. For 
these reasons, and because of the complex interactions among different 
cell types (smooth muscle cells, pericytes, fibroblast, macrophages) 
forming functional blood vessels, in vitro angiogenesis assay must be 
considered a starting point of the research and the in vitro findings have to 
be confirmed in vivo using an animal model.  
 
3.1 TpF-1 induces an angiogenic phenotype in cultured 
endothelial cells 
Endothelial cell proliferation and migration, as well as extracellular matrix 
remodeling, are considered to be key steps of sprouting angiogenesis. 
Proliferation of endothelial cells is indeed essential for developing 
capillaries in the organism; behind tip cells, endothelial stalk cells 
proliferate elongating the new forming capillary. In order to verify whether 
TpF1 could be involved in the angiogenic process during syphilis 
progression, we first tested the ability of TpF1 in inducing human 
endothelial cell proliferation in vitro. To this aim, endothelia cells, seeded 
on a gelatin-coated 24-well plate, were treated with TpF1, VEGF (as 
positive control) or vehicle (saline) and the proliferation of the cells was 
                                                                                                                 Results                                                                                                       
	   55	  
evaluated, after 12 and 24 h of stimulation. 
As shown in Figure 13, TpF1 induces cell proliferation after both 12 and 24 
h in a manner, which is superimposable to that of VEGF.  
 
                                       
                    
Figure 13. TpF1 induces proliferation of endothelial cells.  
Endothelial cells were exposed to 1 µM TpF1,20 ng/ml VEGF (positive control) or vehicle 
(saline). After 12 and 24 h, cells were counted and normalized by the number of plated 
cells (set as 1, dotted line). The graph shows the fold increase in cell number under the 
different conditions. Significance was determined by student’s t-test for data of TpF1 
treated cells and VEGF treated cells versus vehicle-treated cells.  **, p < 0.01 ***, p < 
0.001. 
 
In sprouting angiogenesis, endothelial cells degrade the extracellular 
matrix and, along chemical gradients of pro-angiogenic stimuli, cells 
extend, contract, and throw their rear toward the front and progress 
forward [61]. 
Therefore, we moved to address whether TpF1 was able to stimulate 
endothelial cells migration by taking advantage of a transwell system: in 
this system endothelial cells are placed on the upper layer of a cell 
permeable membrane and a solution containing the test agent is placed 
below the cell permeable membrane. The filter pores are small enough 
(~8 µm) to allow passage of actively migrating cells into the lower 
chamber, avoiding the passive membrane transition driven by gravity.  
Endothelial cells were added to the upper chamber and the number of 
cells migrated into the lower chamber, containing either TpF1 or VEGF or 
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vehicle, was counted at different time intervals. The results showed a pro-
migratory effect of TpF1 similar to that of VEGF  (Figure14). 
 
                                        
 
Figure 14. TpF1 induces migration of endothelial cell. Fast DiI-labeled endothelial 
cells were seeded on the upper chambers of a 24-transwell plate in HE-SFM. 1 µM TpF1, 
20 ng/ml VEGF or vehicle were added to the lower chambers. Migrated cells were 
quantified after 2, 6 and 24 h by a microplate reader (Infinite 200, Tecan) and expressed 
as % of seeded cells. Data are presented as mean ± S.D. of three independent 
experiments. Significance was determined by student’s t-test for data of TpF1 treated 
cells and VEGF treated cells versus vehicle-treated cells. *, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
 
 
As clearly depicted in the graph, TpF1 stimulated migration of 
approximately 38% cells after 2 h, and mobilized more than 54% cells 
after 6 h, reaching 58% after 24 h. During angiogenesis, subsequently to 
proliferation and migration, endothelial cells begin to form organized 
tubules with defined lumens in order to permit a correct blood flow.	  
Since TpF1 stimulated proliferation and migration of endothelial cell, we 
next evaluated the ability of TpF1 to induce vessel formation using an in 
vitro tube formation assay in matrigel.  
Matrigel is a solubilized basement membrane preparation extracted from 
the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in 
extracellular matrix proteins that include laminin (a major component), 
collagen IV, heparan sulfate proteoglycans, and entactin/nidogen (BD 
Falcon). When endothelial cells are seeded on matrigel, in the presence of 
a pro-angiogenic factor, they attach within one hour, migrate toward each 
                                                                                                                 Results                                                                                                       
	   57	  
other, tend to form tubes with a lumen, and develop tight cell–cell and 
cell–matrix contacts [62]. 
                                                           
                        
Figure 15. TpF1 induces endothelial cell organization in microcapillary-like 
structures. Endothelial cells were seeded on matrigel-coated coverslips (area=0.69 cm2) 
and exposed to 1 µM TpF1, 20 ng/ml VEGF or vehicle, for 12 h. Cells were fixed, stained 
with Phalloidin-Alexa Fluor 546 and analyzed by confocal microscopy at 200× 
magnification. Microcapillary-like structures were counted from three different coverslips 
for each experimental condition and expressed as the average of the number of vessels 
per cm2. Data are presented as mean ± S.D. Significance was determined by student’s t-
test for data of TpF1 treated cells and VEGF treated cells versus vehicle-treated cells. *, 
p < 0.05. 
 
We grew endothelial cells in matrigel and stained the cells for actin to 
visualize tube formation. Confocal microscopy images clearly reveal that 
endothelial cells incubated with no agonists tended to cluster together 
forming large aggregates without any tubular organization. On the 
contrary, TpF1 induced marked changes in the cell pattern with the 
formation of tubules assembled by elongation and joining of endothelial 
cells; a similar pattern was observed with VEGF. Quantitative analysis of 
the data showed that the effect of TpF1 was even higher than that of 
VEGF (Figure 15). 
 
3.2 TpF1 promotes synthesis and secretion of IL-8 in 
endothelial cells 
To gain insights into how TpF1 induces angiogenesis in vitro, we decided 
to investigate about the molecular pathway that could be involved in this 
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process. To this aim we have first evaluated gene synthesis and protein 
release of VEGF, the most potent angiogenesis inducer produced by the 
endothelium [63]. 
Endothelial cells, isolated from human cord, were treated with TpF1, 
VEGF or vehicle (saline), harvested at different time points and total RNA 
was isolated for RT-PCR analysis. Culture supernatants of the same cells 
were collected for subsequent quantification of VEGF content by ELISA. 
Interestingly TpF1 did not affect both the expression and the    release of 
VEGF (Figure 16, left panels).  
                   
Figure 16. TpF1 stimulates IL-8 expression. Endothelial cells were exposed to 1 µM 
TpF1 or vehicle (saline) for 2, 6, 18, 24 h and the expression of VEGF (left top panel) or 
of IL-8 (right top panel) was evaluated by real-time PCR. Data were normalized to an 
endogenous reference gene (ribosomal subunit 18S). Values at T0 cells were taken as 
reference and set as 1 (dotted line) and the expression levels for treated cells were 
expressed as n-fold change relative to the expression of T0 cells. Culture supernatants 
from endothelial cells, harvested for quantification of mRNA, were collected and the 
VEGF (left bottom panel) and IL-8 (right bottom panel) protein content was quantified by 
ELISA. Data are expressed as mean ± S.D. of four independent experiments. 
Significance was determined by student’s t-test for data of TpF1 treated cells versus 
vehicle-exposed cells (***, p < 0.001). 
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We next evaluated whether TpF1 promoted the production of IL-8, a pro-
inflammatory chemokine with pro-angiogenic properties, also produced by 
endothelial cells [52].  
In contrast to what observed for VEGF, TpF1 strongly induced both 
expression and secretion of IL-8 (Figure 16, right panels) in a time-
dependent manner suggesting a role for the cytokine in the TpF1-induced 
angiogenic process. 
 
 
3.3 The pro-angiogenic activity of TpF1 in vitro is mediated 
by IL-8  
The role of the chemokine in the TpF1-induced angiogenesis was verified 
by applying an IL-8-blocking antibody to endothelial cells exposed to the 
bacterial protein. Endothelial cells were treated with TpF1, IL-8 or vehicle 
(saline) in presence or absence of an anti-IL-8 blocking antibody and cell 
proliferation was evaluated after 12 and 24 h of stimulation. 
As shown in Figure 17A the presence of the blocking antibody almost 
completely abrogated endothelial cell proliferation, both at 12 and 24 h.  
For the migration assay, we stimulated endothelial cells with TpF1 for 24 
h; the supernatant was then collected and incubated 45 min at 37°C with  
the anti-IL-8 antibody before adding to the lower chamber of the transwell 
system, where fresh endothelial cells seeded on the filter of the upper 
chamber. By using this experimental set-up, we verified that TpF1-induced 
migration was also reduced upon the blockage of IL-8, slightly after 2 h, 
but significantly after 6 and 24 h (Figure 17B). 
Finally, in order to unravel the IL-8-dependency of the angiogenic process 
due to TpF1, we repeated the in vitro tube formation assay. We grew 
endothelial cells in matrigel in the presence of TpF1 with or without the IL-
8-blocking antibody, before proceeding with the staining of the cells for 
actin to visualize tube formation. 
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Figure 17. IL-8 is required for the pro-angiogenic activity of TpF1. (A) Endothelial 
cells were exposed to TpF1, as in Figure 1A, in presence or absence of 1 µg/ml anti-IL-8 
blocking antibody; after 12 and 24 h cells were counted and normalized by the number of 
plated cells (set as 1, dotted line). The graph shows the fold increase in cell number 
under the different conditions. (B) Endothelial cells, grown to confluence in a 24-well 
plate, were exposed to TpF1 for 24 h. Supernatant was collected and incubated or not 
with 1 µg/ml anti-IL-8 blocking antibody for 45 min at 37°C, before transferring to the 
lower chamber of a 24 transwell plate with Fast DiI-labeled endothelial cells seeded on 
the upper chamber. Migrated cells were quantified after 2, 6 and 24 h as before. (C) 
Endothelial cells seeded on matrigel-coated coverslips (area=0.69 cm2) were exposed to 
1 µM TpF1 for 12 h, in presence or absence of 1 µg/ml IL-8 blocking antibody. 
Microcapillary-like structures were counted from three different coverslips for each 
experimental condition and expressed as the average of the number of vessels per cm2. 
Data are expressed as mean ± S.D. of four independent experiments. *, p < 0.05; **, p < 
0.01; ***, p < 0.001.  
 
Confocal microscopy analysis confirmed the ability of TpF1 to promote the 
capillary formation; conversely, when IL-8 was blocked, cells clustered 
together forming large aggregates, showing a morphology resembling the 
negative control where cells were clustered and no elongations and joining 
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of endothelial cells were detectable; quantitative analysis of the formed 
tubules confirmed the inhibitory effect of the anti-IL-8 antibody (Figure 
17C). 
 
3.4  TpF1 increases cAMP in endothelial cells 
Established the involvement of the chemokine in the TpF1-induced 
angiogenesis we decided to focus our study on the signaling pathway 
evoked by TpF1 leading to the IL-8 gene transcription. 
It is known that under inflammatory conditions, especially in presence of 
IL-1β, the expression of CXC chemokine, and in particular of IL-8, is 
promoted and it follows the activation of two transcription factors: NF-κB 
and CREB (cAMP response element-binding protein) [54]. Accordingly, 
the consensus sequence of both CREB and NF-κB are located in the IL-8 
promoter [64], [65].  
Since also TpF1 had pro-inflammatory properties [29], and it induced IL-8 
secretion, it was plausible that it modulated the same transcription 
pathway involved in the IL-1β signaling. Therefore, we sought to determine 
whether CREB and NF-κB mediated the TpF1-induced IL-8 expression in 
endothelial cells.  
Recent evidence suggest that CREB and NF-κB may share an upstream 
common activator, the adenylate cyclase [66], [67]. 
Adenylate cyclases is an enzyme, located in the plasma membrane, which 
catalyzes the conversion of adenosine triphosphate (ATP) into 3’,5’-cyclic 
AMP (cAMP) and pyrophosphate. cAMP is a second messenger, which in 
turn, through a number of different signal pathways, leads to the activation 
of both CREB and NF-κB thus promoting the expression of the IL-8 gene 
(Figure 18).  
The latter consideration prompted us to investigate the cAMP dynamics in 
living endothelial cells exposed to TpF1. Endothelial cells were transfected 
with the genetically encoded, FRET-based cAMP sensor Epac1  [55], and 
imaged under a fluorescence microscope.  
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Figure 18. Schematic representation of c-AMP-triggered activation of CREB and NF-κB.  
 
Epac1 sensor consists of a single cAMP-binding site from human Epac1 
protein flanked by YFP and CFP. Binding of cAMP to the sensor leads to a 
conformational change of the protein, resulting in a decrease of the YFP 
fluorescence due to FRET and a concomitant increase in CFP 
fluorescence [68].  
 
 
 
 
Figure 19. TpF1 increases cytosolic cAMP in endothelial cells. (A) Representative 
kinetics of cAMP changes recorded in a Epac1-expressing endothelial cells, upon 
addition of 1 µM TpF1, followed by 100 µM IBMX and by 25 µM forskolin. cAMP 
variations are presented as DR/R0. The average ΔR=R-R0 increases (mean ± SEM, n=9) 
are presented in (B). *, p < 0.05; ***, p < 0.001 
 
CREB 
Adenylate 
 cyclase 
P 
IkBα 
IkBα p65 
p50 
ATP 
cAMP 
CBP 
P 
NF-κB 
TTTCGTCA GGAATTTCC 
CREB NF-kB IL-8 
P 
p65 
p50 
P CBP 
CREB 
N κB 
                                                                                                                 Results                                                                                                      
	   63	  
TpF1 application induced a cAMP increase in endothelial cells, which was 
potentiated by the inhibition of phosphodiesterases by 3-isobutyl-1-
methylxanthine (IBMX).  
The TpF1-induced cAMP accounted for about 30% of the maximal cAMP 
generated in endothelial cells, when adenylate cyclases were maximally 
activated by the direct activator forskolin and phosphodiesterases were 
maximally inhibited. 
Figure 19A shows a typical kinetic of ΔR/R0 in an endothelial cell 
challenged with TpF1, followed by the application of IBMX and forskolin. 
Figure 19B summarizes the average ΔR/R0 changes induced by TpF1, 
alone or plus the drugs, in Epac1-expressing endothelial cells (n=9). 
 
 
3.5 NF-κB and CREB are activated by TpF1 in endothelial 
cells. 
Since CREB is activated via phosphorylation at Ser133 by several 
different kinases, including MAPK, but mainly PKA (cAMP-dependent 
protein kinase), we monitored the phosphorylation level of CREB in 
endothelial cells exposed for 30 min to TpF1. Figure 20A shows that TpF1 
promoted the phosphorylation of CREB to a similar extent than the 
adenylate cyclase activator forskolin.  
This result was confirmed by a quantitative kinetic performed with a 
phospho-CREB cell-based ELISA (Figure 20B): phosphorylation was 
detectable as early as after a 5 min-exposure to the bacterial protein and it 
remained high until 30 min, before dropping down to the basal level after 
60 min. As before, the extent of phosphorylation induced by TpF1 was 
similar to that triggered by forskolin. For addressing whether TpF1 
activated NF-κB too, we first evaluated the phosphorylation of the NF-κB 
p65 subunit, an event required for transactivation of target genes [69]. 
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Figure 20. TpF1 activates CREB in endothelial cells. (A) Endothelial cells were 
exposed to 1 µM TpF1, 25 µM forskolin or vehicle (saline). After 30 min, cells were lysed 
and processed for western blot; p-CREB and actin were revealed with specific  
antibodies. Graph shows the ratio between p-CREB and actin (n=4). (B) Endothelial 
cells were exposed to 1 µM TpF1, 25 µM forskolin or vehicle; at the indicated time points, 
the phosphorylation of CREB was evaluated by ELISA assay. For each sample, data 
were normalized to the total CREB protein. Normalized fluorescence value of cells at time 
0 (T0) was taken as reference and set as 1 (dotted line) and CREB phosphorylation of 
treated cells was expressed as fold change of T0 cells. Data are expressed as mean ± 
S.D. of three independent experiments. Significance was determined by student’s t-test 
for data of agonist-treated cells versus vehicle-exposed cells. **, p < 0.01; ***, p < 0.001. 
 
As shown in Figure 21A, depicting the activation state of p65 after a 30 
min-incubation with agonists, TpF1 promoted the phosphorylation of the 
subunit similarly to LPS, adopted as positive control.  
A quantitative kinetic of the phosphorylation of the NF-κB inhibitor κBα 
(IκBα), an event that precedes its proteasomal degradation and the 
translocation of the active form of NF-κB to the nucleus [70], was also 
performed. 
Figure 21B shows that the exposure of endothelial cells to TpF1 increased 
by 1.5 folds the phosphorylation state of IκBα, similarly to what observed 
in case of LPS intoxication. The phosphorylation of IκBα which remained 
high at 15 min of incubation, decreased to the basal level thereafter, in 
accordance to the rapid degradation of the inhibitor by the proteasome. 
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Figure 21. TpF1 activates NF-κB in endothelial cells. (A) Endothelial cells were 
exposed to 1 µM TpF1, 1 µg/ml LPS or vehicle. After 30 min, cells were processed for 
western blot; p-p65 and actin were revealed with specific  antibodies. Graph shows the 
ratio between p-p65 and actin (n=4). (B) Endothelial cells were exposed to 1 µM TpF1, 
1 µg/ml LPS or vehicle; at indicated time point the phosphorylation of IκBα was evaluated 
by ELISA assay. For each sample, data were normalized to the GAPDH protein. 
Normalized fluorescence value of cells at time 0 (T0) was taken as reference and set as 1 
(dotted line) and IκBα phosphorylation of treated cells was expressed as fold change of 
T0 cells. Data are expressed as mean ± SD of three independent experiments.  
Significance was determined by student’s t-test for data of agonist-treated cells versus 
vehicle-exposed cells. *, p < 0.05. 
 
 
3.6 The activation of CREB and NF-κB is essential for 
TpF1-induced IL-8 production 
Based on the evidence that TpF1 activated both CREB and NF-κB, we 
next evaluated whether these two transcription factors were those 
responsible for the increased expression and secretion of IL-8, observed 
in endothelial cells exposed to the bacterial protein. 
 To this aim, we took advantage of two inhibitors: 2-naphthol-AS-E-
phosphate (KG501) and N4-[2-(4-phenoxyphenyl)ethyl]-4,6 
quinazolinediamine (QNZ). KG501 is a small molecule that binds to the 
transcription co-activator CREB-binding protein (CBP) and blocks its 
interaction with the active form of CREB, p-CREB [71]. QNZ, also called 
EVP4593, is antagonist of the NF-κB pathway activation, acting by 
inhibiting store-operated calcium (Ca2+) entry (SOC) [72]. 
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Figure 22. CREB is NF-κB are essential for the production of IL-8 by endothelial 
cells exposed to TpF1. Endothelial cells were pre-incubated or not pre-incubated for 30 
min with the CREB inhibitor KG501 (left panel) or the NF-κB inhibitor QNZ (right panel), 
before the exposure to 1 µM TpF1 or vehicle. At the indicated time points, culture 
supernatants were collected and evaluated for their IL-8 content by ELISA. Data are 
expressed as mean ± SD of three independent experiments. ***, p < 0.001. 
 
Figure 22 shows that a 30 min pre-incubation of endothelial cells with each 
inhibitor results in a significant reduction of the secretion of IL-8 triggered 
by TpF1; this result definitively supports the conclusion that CREB and 
NF-κB, which are activated by TpF1, are essential for IL-8 gene 
expression induced by the bacterial protein. 
 
3.7 TpF1 has angiogenic activity in living zebrafish 
We previously said that in vitro angiogenesis studies should be considered 
as a starting point rather than an endpoint of our research; due to the 
complexity of the angiogenic process, the in vitro findings must be 
confirmed in an animal model. Zebrafish has recently gained much 
attention as model to study the in vivo angiogenesis. Zebrafish embryos 
develop outside of the uterus, and this permits to follow the animals during 
its development. Moreover, the possibility to inhibit the pigmentation by a 
chemical treatment, guarantees that the embryos remain transparent. 
Zebrafish is relatively easy and cheap to maintain, compared to rodents. 
They produce many eggs per each breeding cycle, and the embryonic 
development is fast [56]. All these characteristics make zebrafish a useful 
tool for studying angiogenesis in vivo. In the last decades many kinds of 
transgenic lines expressing fluorescent proteins in a cell-type specific 
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manner have been generated. Among them, the fli1a:EGFP transgenic 
line has become a very useful tool for examining vascular development in 
zebrafish. Fli1:EGFP transgenic line expresses EGFP (enhanced green 
fluorescent protein) under the control of the promoter for fli1, a known 
endothelial cell marker in mouse [73], which is also expressed during 
vascular development in zebrafish embryos [74]. Application of this 
vascular-specific transgenic zebrafish, in conjunction with confocal 
microscopy analysis, allows a precise and detailed in vivo observation of 
the embryonic vasculature in a vertebrate animal model [56]. 
 
3.5.1 TpF1 induces new blood vessels formation in zebrafish	  
In a first set of experiments we based on the angiogenic activity assay 
developed by Serbedzija and colleagues [56] and consisting in measuring 
the length of SIVs (sub intestinal veins) in animals injected with potential 
angiogenic molecules in the yolk.  
 
               
Figure 23. TpF1 promotes SIVs sprouting in zebrafish Comparison of the blood 
vessel patterning, at the sub intestinal area (SIVs), between vehicle- and TpF1-treated 
larvae. Animals were injected in the yolk 1 dpf and the alkaline phosphatase-based assay 
was performed at 3 dpf. Graph represents the fold increase in SIV length referring to the 
value of vehicle-treated animals, set as 1. Data are expressed as mean ± S.D. (n= 20 for 
each treatment). Significance was determined by student’s t-test for data of TpF1-treated 
fish versus vehicle-exposed fish. ***, p<0.001.   
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The SIVs assay has the advantage of being low tech; on the other hand, it 
has high variability and works ex vivo.  
With this first screening, we observed, 3 dpf (days post fertilization), a 
significant change in the shape and length of SIVs in 1 dpf TpF1-injected-
fishes (Figure 23). In order to obtain further insights into TpF1 activity in 
vivo, we performed a zebrafish microangiography. Microangiography is a 
simple technique in which a fluorescent dye is injected directly into the 
Sinus Venosus and/or the Posterior Cardinal Vein, allowing the rapid 
labeling and easy detection of vessels [75]. We injected zebrafish early 
larvae at 1 dpf, with TpF1 or vehicle (saline); at 3 dpf a solution of FITC-
labeled 70 kDa-dextran into the cardiac venous sinus was injected and live 
fish were then analyzed using a Leica inverted microscope. 
 
               
Figure 24. TpF1 increases the CA-CV distance in zebrafish Comparison of the blood 
vessel patterning at the trunk-tail region, between vehicle- and TpF1-treated larvae. The 
circulatory tree was revealed by FITC-labelled 70 kDa-dextran, injected into the cardiac 
venous sinus of 3 dpf old larvae. Animals were injected with vehicle or TpF1 in the yolk at 
1 dpf  and images were taken at 3 dpf.  Graph shows the mean ±  S.D. of the distance 
between the caudal aorta (CA) and the caudal vein (CV) (n= 12 for each treatment). 
Significance was determined by student’s t-test for data of TpF1-treated fish versus 
vehicle-exposed fish. ***, p<0.001.	  	   
 
In accordance to previous data, microangiography of TpF1-injected fish 
revealed a significant increase of the distance between the Caudal Aorta 
(CA) and the Caudal Vein (CV) (Figure 24).  Based on these results, we 
decided to fully exploit the in vivo potential of zebrafish by measuring the 
total level of integrated density of the intestinal circulation in the sector 
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from the 8th to the 14th intersomitic vessel (Figure 25A, red box). The idea 
of focusing the analysis on the intestinal circulation relied on the fact that 
TpF1, injected in the yolk sac, was able to diffuse posterior in its own 
extension, as revealed by using a rhodamine-conjugated TpF1  (data not 
shown).  
 
Figure 25. New blood vessels formation in zebrafish after TpF1 treatment. (A) 
Illustration of the vascular system of a 4 dpf larva; regions for image acquisition are 
indicated by the colored boxes (panel A). Embryos at 2 dpf were injected with 10 µM 
TpF1 or vehicle. Injections were performed either in the yolk (B) or in the caudal vein 
plexus (C). Representative images were taken at 4 dpf by confocal microscopy at 20× 
and 40× magnification, respectively. Scale bar: 100 microm. Graphs summarize data of 
six independent experiments and are expressed as mean ± S.D of integrated density of 
fluorescence in the green channel. Significance was determined by student’s t-test for 
data of TpF1-treated fish versus vehicle-exposed fish. *, p < 0.05. Squares indicates the 
region of interest analyzed by VOLOCITY 6.0 software. 
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To this aim, we took advantage from the transgenic fluorescent zebrafish 
Tg(fli1:EGFP)y1 [55]. Fli1 is a transgenic zebrafish line expressing 
enhanced GFP in the entire vasculature, under the control the fli1 
promoter. 
Two dpf transgenic fli1:EGFP larvae were injected with TpF1 at the 
concentration of 10 µM in the yolk sac. After injection, normally shaped 
and positively injected larvae were processed for imaging studies. As 
shown in Figure 25B, embryos injected with TpF1 revealed a significant 
fluorescence increase in the intestinal circulation at two days post injection 
when compared with vehicle-injected controls.  
To confirm the angiogenic effect, we also injected 2 dpf larvae in the 
caudal plexus. Then, the integrated fluorescence of the caudal plexus, in 
the segment between the 21st and 25th intersomitic vessel (Figure 25A, 
green box), was computed in fli1:EGFP fish injected with TpF1 and the 
measure compared with vehicle-injected fish (Figure 25C). Results 
confirmed a consistent and significant angiogenic activity by TpF1 also in 
the caudal plexus.  
 
 
3.5.2 TpF1 promotes synthesis of IL-8 in zebrafish 
Finally, we evaluated the expression of the angiogenic factors VEGF and 
IL-8 in zebrafish exposed to the bacterial protein, in order to further 
corroborate with the in vivo model, the in vitro evidence.  
We found that the mRNA level of the two isoforms of the IL-8 gene was 
up-regulated after treatment with TpF1 at 2 days post-injection, while the 
expression level of VEGF was comparable to that of vehicle-injected 
controls (Figure 26). These results, demonstrating that the angiogenic 
effect of TpF1 in vivo is paralleled by the increase of IL-8 expression, 
support the conclusion that this cytokine is crucial for the pro-angiogenic 
activity of TpF1. 
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Figure 25. TpF1 induces IL-8 gene expression in zebrafish. Wt animals were injected 
with 10 µM TpF1 or vehicle. The injection was applied in the yolk at 2 dpf. RNAs were 
extracted at 4 dpf and the expression of VEGF, IL-8a and IL-8b was evaluated by real-
time PCR. For each sample data were normalized to the endogenous reference gene β-
actin. Vehicle-treated fish were taken as reference and set as 1; expression levels of 
TpF1-exposed fish were expressed as n-fold change relative to the expression level of 
vehicle-treated fish. Data represent mean ± S.D. (n=30 larvae for each treatment). 
Significance was determined by student’s t-test for data of TpF1-treated fish versus 
vehicle-exposed fish. ***, p < 0.001.  
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4. Discussion 
 
 
Syphilis is a chronic and multistage disease caused by the spirochete 
Treponema pallidum. Despite it could be cured with a simple and 
inexpensive antibiotic treatment, syphilis is worldwide spread and 
represent a global health problem; even today it is considered the major 
sexual transmitted disease. Nowadays none vaccine to prevent syphilis 
has been formulated yet, in particular due to the difficulties in cultivating T. 
pallidum in vitro, because of its peculiarities, (striking lack of metabolic 
capabilities, sensitivity to oxygen and temperature) which makes more 
difficult to study this pathogen, as well as the identification of its virulence 
factors. Although little is known about the mechanism of syphilis 
pathogenesis and how the bacterium causes the typical clinical 
manifestations that accompany the different stages of the disease, it is 
widely accepted that T. pallidum is able to invade and survive in a wide 
variety of tissues and organs [1] and that it activates the endothelium 
promoting new blood vessels formation [36]. Angiogenesis, in this contest, 
could be exploited by the bacterium to uptake nutrients directly from the 
host and, taking advantage of the increased vascular permeability 
characterizing first stages of angiogenesis [37], to access to and egress 
from the bloodstream, resulting in systemic spread. Despite the pivotal 
role that angiogenesis could play in syphilis progression, bacterial factors 
involved in this process are still unknown. Another distinctive feature of 
syphilis relies on the capacity of T. pallidum to elicit a strong inflammation 
and, at the same time, to avoid the complete clearance exerted by the 
immune response of the host leading, thus, to chronic disease. In this 
regard it has been recently demonstrated by our research group, that the 
mininferritin TpF1, a major treponemal antigen, promotes inflammasome 
activation with the subsequent release of pro-inflammatory cytokines. 
Moreover, we observed that TpF1 promotes the development of T 
regulatory cells, the main effectors in the down-modulation of immune 
response [29].  
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TpF1 is a dodecameric glycoprotein of 190 kDa belonging to the Dps-like 
family, highly immunogenic, localized in the periplasmic space of the 
bacterium and probably released after Treponema autolysis [22]. TpF1 is 
homolog to another immunomodulant Dps-like protein, HP-NAP, produced 
by Helicobacter pylori. 
HP-NAP is known to interact with different cell types (neutrophils, 
monocytes, dendritic cells) and to modulate their activity; moreover, it also 
binds to endothelial cells, in which it is internalized by transcytosis. 
Considering the role played by TpF1 in syphilis pathogenesis, the 
homology existing between HP-NAP and TpF1, and the fact that 
angiogenesis is characteristic of secondary syphilis, we decided to verify if 
TpF1 could interact and activate the endothelium promoting the formation 
of new blood vessels.  
In a series of pilot experiments, we investigated whether TpF1 promoted 
proliferation and migration of endothelial cells. To this purpose we used 
human umbilical vein-derived endothelial cells (HUVECs), isolated from 
umbilical cords of healthy donors. 
We found that TpF1 promoted cell proliferation, as well as cell migration. 
In accordance, endothelial cells, seeded on matrigel,, tend to form 
microcapillar-like structures in the presence of TpF1. 
Notably, the effect of TpF1 on endothelial cells was superimposable to that 
observed in the presence of the vascular endothelial growth factor 
(VEGF), the best characterized angiogenesis promoter [76] 
In order to gain insights into how TpF1 induces angiogenesis in vitro, we 
evaluated the production of VEGF and IL-8, a chemokine with a potent 
pro-angiogenic activity [52]; both of the factors are produced by 
endothelial cells. Interestingly RT-PCR and ELISA analysis revealed that 
VEGF production was not affected upon TpF1 stimulation; conversely, 
TpF1 strongly induced both IL-8 gene expression and protein release in a 
time dependent manner. The fact that the chemokine was crucial for the 
pro-angiogenic activity of TpF1 was proven by the inhibitory effect exerted 
by a specific IL-8 blocking antibody: it inhibited endothelial cell proliferation 
and migration as well as the formation of micro capillary-like structures. 
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Is known that under inflammatory conditions, especially in presence of IL-
1β, the expression of IL-8 is promoted and it follows the activation of two 
transcription factors: NF-κB and CREB (cAMP response element-binding 
protein) [54].	   Accordingly, the promoter of IL-8 gene contains the binding 
sites for both the factors [77]. 
Since also TpF1 has pro-inflammatory properties [29], it was plausible that 
it modulated the same transcription pathway involved in the IL-1β 
signaling. Emerging findings suggest that cAMP, produced by adenylate 
cyclases, is able to induce gene transcription through the activation of 
several protein kinases, with the subsequent phosphorylation of both 
CREB and NF-κB [66], [67]. The analysis of cAMP dynamics in living 
endothelial cells revealed that TpF1 promotes cAMP production. 
Moreover, we found that TpF1 triggered the phosphorylation of CREB, NF-
κB and IκBα (a direct negative regulator of NF-κB); notably, the inhibition 
of the two transcription factors resulted in a significant reduction in IL-8 
secretion. This evidence definitively supports the conclusion that CREB 
and NF-κB, which are activated by TpF1, are essential for the IL-8 gene 
expression induced by the bacterial protein. 
Finally, to corroborate the in vitro findings, we evaluated the angiogenic 
properties of TpF1 in vivo, using zebrafish as animal model. Results 
obtained by both wild type and transgenic fli1:EGFP zebrafish, injected 
with TpF1, confirmed the ability of the treponemal toxin to induce, also in 
vivo, the formation of new blood vessels.  
Finally, we found that the expression of the two isoforms of the IL-8 gene 
was up-regulated in zebrafish after TpF1 injection, while the mRNA level 
of VEGF was not affected. The fact that TpF1 triggers the formation of 
new blood vessels and, simultaneously, it stimulate IL-8 expression and 
secretion, supports the conclusion that this chemokine play a pivotal role 
in the pro-angiogenic activity of TpF1, also in vivo. 
In conclusion, with this study we have identified a treponemal factor 
endowed with pro-angiogenic activity that could be involved in the 
angiogenic process that accompanies the early stages of syphilis. It is 
conceivable that angiogenesis plays a central role in syphilis progression, 
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probably because it provides T.pallidum of nutrients but also because it 
facilitates the dissemination of the bacterium within the host, resulting in 
systemic spread. 
Our evidence adds a new piece to the complicated puzzle of a disease still 
affecting worldwide approximately 12 million of people every year.  
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